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ABSTRACT 
This thesis consists of two related studies directed at aspects of M. 
tuberculosis biology. The first focuses on deciphering gene-regulatory circuits 
from ChIP-seq data, and the second focuses on alternative strategies for 
combatting drug-resistant infections. 
 The first study describes Binding Resolution Amplifier and Cooperative 
Interaction Locator (BRACIL), a post-peak-caller computational method that 
predicts transcription-factor (TF) binding sites with high-resolution as well as 
cooperative TF interactions derived from ChIP-seq data. BRACIL integrates 
ChIP-seq coverage with motif discovery from a signal-processing perspective 
and uses a blind-deconvolution algorithm that predicts binding-site locations and 
magnitudes. BRACIL also explicitly considers a second-order signal, represented 
by DNA fragments with two sites bound simultaneously, and uses it to predict 
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cooperative interaction. Cooperative interaction indicates that the binding to a 
first site influences the probability of binding to a second site. This method 
estimates the probability of a binding configuration from the ChIP-seq coverage 
and performs a likelihood ratio test to predict cooperative interaction. As a proof 
of principle, I validated this method using M. tuberculosis transcription factor 
DosR. 
 The second study focuses on strategies to fight antibiotic resistance. In 
particular, recent reports have shown the existence of treatment conditions 
(called “antiR”) that select against drug-resistant strains.  I used a mathematical 
model of infection dynamics and immunity to simulate the growth of resistant and 
sensitive pathogens under different treatment conditions (no drugs, antibiotic 
present, and antiR), and could show how a precisely timed combination of 
treatments can defeat resistant strains. This analysis suggested that a time-
scheduled, multi-treatment therapy could lead to complete elimination of both 
sensitive and resistant strains.  Also, my results indicated that the time necessary 
to turn a resistant infection into a sensitive one (“tclear”) depends on the 
experimentally measurable rates of pathogen division, growth and plasmid loss. 
Additionally, I estimated tclear for a specific case, using available empirical data, 
and found that resistance may be lost up to 15 times faster under antiR treatment 
as compared to a no-treatment regime. Finally, an extension of these findings to 
population models provides quantitative support for therapeutic plans to clear 
antibiotic-resistant infections, including novel drug-cycling strategies. 
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Part I 
Deciphering regulatory circuits from ChIP-seq data
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Chapter 1 
Background on studies of gene regulatory network  
 
This chapter introduces the recent advances in the studies of gene regulatory 
network, focusing in the identification of DNA regions that are bound by 
regulatory proteins called transcription factors. In particular, I describe the 
thermodynamics fundamentals for the study of gene regulation and describe the 
concepts of chromatin immunoprecipitation followed by sequencing (ChIP-seq), 
the state of art technique to map the gene regulatory network. Finally, I describe 
the current methods of ChIP-seq analysis and introduce the underexplored 
opportunities that will lead to the original contribution of this work. 
 
The success of an organism depends on expressing the right set of genes in 
response to different environmental challenges. Regulatory proteins, namely, 
transcription factors (TF) mediate this choice. The TFs are able to recognize and 
bind specific DNA sequences, promoting or blocking the recruitment of RNA-
polymerase and the initialization of transcription (Browning and Busby 2004). In 
order to understand the molecular basis of gene regulation, it is important to 
characterize and identify the mechanisms that drive transcription factor binding in 
vivo.   
Gene regulation can be studied from a thermodynamics point of view. In this 
context, a DNA sequence contains multiple binding sites, which may be bound or 
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not. Each distinct configuration describes a binding conformation, indicating 
which sites are bound and which sites are unbound. The thermodynamics 
representation associates a probability to each possible conformation. This 
approach provides a quantitative understanding of gene regulation and has been 
used for predicting cell phenotypes, such as gene expression and embryo 
development (Zinzen et al. 2006; Segal et al. 2008; Segal and Widom 2009; He 
et al. 2010). The accuracy of such models depends on associating the correct 
probability for each conformation. In order to obtain reliable predictive power, it is 
necessary to understand the underlying factors that contribute to the binding 
conformation probabilities. 
The probability of each conformation depends on the affinity between a TF 
and the corresponding binding sites (Maerkl and Quake 2007; Segal and Widom 
2009; Zhao et al. 2009; Stormo and Zhao 2010). Motif discovery has been used 
for this purpose (Segal et al. 2008; He et al. 2010), but motif presence alone is 
not sufficient to characterize the binding under physiological conditions (Barski et 
al. 2007; Robertson et al. 2007; Kaplan et al. 2008; Kim and O'Shea 2008; Visel 
et al. 2009; Gordon et al. 2010; MacQuarrie et al. 2011). The binding observed in 
vivo (Valouev et al. 2008) does not correlate well with affinity observed in vitro 
(Berger and Bulyk 2009). Also, only a fraction of sites are bound under 
physiological conditions (Robertson et al. 2007; Visel et al. 2009; MacQuarrie et 
al. 2011). For example, p300 contains many binding sites in the mouse genome, 
however a different subset of sites are bound in different types of tissues (Visel et 
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al. 2009). One of the reasons for these differences is that the site accessibility 
varies under different physiological conditions (Barski et al. 2007; Kaplan et al. 
2008; Kim and O'Shea 2008; Gordon et al. 2010; Pique-Regi et al. 2011).  
In addition, binding is affected by the presence of multiple sites inside the 
same regulatory region (Johnson et al. 2007; Chauhan and Tyagi 2008; Valouev 
et al. 2008; Vasudeva-Rao and McDonough 2008; Chauhan et al. 2011). The 
presence of multiple sites is important to tune the binding dynamics, especially 
due to cooperative interactions (Gertz et al. 2009). Also, the position of a site 
might indicate whether binding activates or represses gene expression 
(Oppenheim et al. 2005; Larochelle et al. 2006). Thus, an accurate 
understanding of the gene regulatory network depends on finding the number 
and precise location of binding sites as well as possible interactions among them 
at each regulatory region. 
Advances in the sequence technology brought new opportunities to map the 
gene regulatory network in genome scale. Chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) (Barski et al. 2007; Johnson et al. 2007; 
Robertson et al. 2007), and more recently, ChIP-exo (Rhee and Pugh 2011) are 
currently the most advanced technologies for this purpose. A map of the 
regulatory network represents the binding regions for each transcription factor. 
The principle of chromatin immunoprecipitation consists of using antibody 
selection to purify DNA fragments that are bound by the TF of interest. Following, 
the sequencing technology provides tags that identify the purified DNA. Those 
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tags are aligned to a reference genome and yield an enriched coverage around 
binding regions. 
The initial studies of ChIP-seq (Barski et al. 2007; Johnson et al. 2007; 
Robertson et al. 2007) focused on identifying and validating the enriched regions 
for well-characterized DNA binding factors (Hartman et al. 2005; Gaszner and 
Felsenfeld 2006; Mortazavi et al. 2006; Heintzman et al. 2007). Subsequent 
papers described the underlying signals of ChIP-seq and developed algorithms 
to identify enriched regions (also known as peak-callers) (Kharchenko et al. 
2008; Valouev et al. 2008; Zhang et al. 2008; Lun et al. 2009). One of the most 
successful signatures identified to date is a peak shift between the coverage of 
the forward and reverse strand. This signature improves the sensitivity of binding 
site detection (Kharchenko et al. 2008; Valouev et al. 2008) and was used to 
develop a benchmark for ChIP-seq analysis (Rye et al. 2011). The integration of 
sequence motifs and ChIP-seq coverage has also been proposed to improve 
sensitivity of binding site detection (Boeva et al. 2010; Guo et al. 2012).  
Multiple peak callers have been proposed (Pepke et al. 2009; Wilbanks and 
Facciotti 2010; Rye et al. 2011), but little attention was given to the physical and 
regulatory properties inside each enriched region (Lun et al. 2009; Salmon-Divon 
et al. 2010). One of the earliest attempts in this direction is csdeconv (Lun et al. 
2009) . Csdeconv considers ChIP-seq coverage in the context of a signaling 
process and uses a blind-deconvolution algorithm to identify multiple binding 
sites inside an enriched region. However, the application of csdeconv has not 
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been practical for data sets with large number of enriched regions due to its high 
computational cost (Wilbanks and Facciotti 2010). 
The next two chapters present the original contribution of this research to the 
analysis of ChIP-seq data. This work have built on the concepts introduced by 
csdeconv to develop Binding Resolution Amplifier and Cooperative Interaction 
Locator (BRACIL), a new method that improves computational performance, 
improves the spatial resolution of binding site detection, and predicts cooperative 
interactions. BRACIL enhances the regulatory details of the enriched regions and 
is a complementary step to the current state of ChIP-seq analysis (Furey 2012). 
BRACIL uses a blind-deconvolution approach that explicitly integrates ChIP-seq 
coverage with motif discovery. This algorithm takes advantage of the high-
resolution information provided by motif discovery, while the ChIP-seq coverage 
used to filter out motifs that do not contribute to the binding signal. I also modeled 
a second order signal that represents DNA fragments with two sites bound 
simultaneously, as the double-binding signal. The double-binding signal improves 
binding site detection and allows a novel application in the ChIP-seq analysis: 
detection of cooperative interaction. 
 The following two chapters describe the concepts and application for this 
new model. The advantages of the new model are illustrated in two biological 
applications: (i) detecting binding sites with single-nucleotide resolution and (ii) 
detecting cooperative interactions. Chapter 2 focuses in the first application., 
detecting binding sites with single-nucleotide resolution. It formally describes a 
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signaling representation of how in vivo binding translates into the ChIP-seq 
coverage and describes a mathematical solution for the binding site impulse 
response with a physical interpretation for its parameters. Specifically, the 
parameters are related to physical properties of DNA shearing. Chapter 3 
focuses in predicting cooperative interaction from ChIP-seq coverage. It 
describes a relationship between binding thermodynamics and impulse response 
magnitudes and provides a formal statistical test to evaluate cooperative 
interaction. The proof of principle of both applications were validated using a 
reference set of 47 binding sites that includes cooperative interaction (Chauhan 
et al. 2011).  
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Chapter 2 
Theoretical Model of the ChIP-seq signal provides binding site detection 
with high-resolution. 
 
In this chapter I explain the fundamentals of ChIP-seq in a signal processing 
perspective and use it to predict binding site locations with high resolution. The 
signaling representation considers each binding site as a source of an impulse 
signal that is translated, according to some impulse response, into the observed 
ChIP-seq coverage. Based on this representation, I describe a blind-
deconvolution model that predicts binding site locations from the ChIP-seq 
coverage. I present how this framework integrates ChIP-seq coverage with motif 
discovery and use it to predict binding site locations with high-resolution. 
Moreover, I present a physically motivated model that describes the impulse 
response as an extreme value distribution and show a relationship of the impulse 
response parameters to physical properties of DNA shearing around a binding 
site. 
 
2.1 Sequence integrated blind-deconvolution model 
As in csdeconv (Lun et al. 2009), my method approaches the ChIP-seq process 
from a signal identification perspective (Fig. 2.1). In this context, an impulse 
signal represents a binding site and emits an impulse response. The sum of all 
impulse responses generates the observed ChIP-seq coverage (see Fig. 2.1A). I 
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have developed a blind-deconvolution algorithm that identifies the binding site 
locations and magnitudes from ChIP-seq coverage (Fig. 2.1B). In this algorithm, 
the term ‘blind’ indicates that the parameters for the impulse response have to be 
learned from the data. Also, the method exploits the information contained in the 
genome sequence, by means of motif discovery, to constrain the search space 
and improve the resolution of binding site detection. 
 The blind-deconvolution algorithm consists of two iterative steps (Fig. 
2.1B): one that updates the magnitude and location of the binding sites (ML step) 
and one that updates the shape of the impulse response (P step).  These steps 
are alternated until convergence. This iterative process is computationally 
expensive and explains why csdeconv (Lun et al. 2009) application is restricted 
to data sets that contains only a few enriched regions (Wilbanks and Facciotti 
2010). My method achieves improved computational efficiency by training the 
parameters of the impulse response in only a subset of the enriched regions (see 
section 2.5). This simplification reduces the number of regions evaluated in the 
iterative part of the algorithm and reduces the computational cost in about two 
times the number of iterative steps. Moreover, after the parameters of the 
impulse response are learned, the problem reduces to a simple deconvolution 
process (represented by the ML step). Also, the deconvolution of each enriched 
region becomes independent from each other and the ML step can be processed 
in parallel. 
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Figure 2.1: Illustration of the integrated model used to detect binding sites at high-
resolution. (A) The binding sites are a source of a signal. Each binding site (purple box) emits an 
impulse response (blue upward arrow) that can be observed in the coverage of the ChIP-seq data 
(A-right part). If two sites are close to each other, the observed data shows an overlap of the 
impulse responses from each site. (B) Illustration of the algorithm for binding site detection. The 
blind-deconvolution algorithm is broken in two parts to optimize the computational efficiency (see 
inset legend box for detailed meaning of each line and color). First, both the ML and P steps are 
applied in a subset of enriched regions to estimate the parameters for the impulse response (B-
top). Following, the ML step predicts the binding site locations for all regions in parallel (B-bottom-
right). From the output of the deconvolution process, it predicts a binding motif. This motif predicts 
potential binding sites that constrain the search space for a second round of the blind-
deconvolution algorithm. (C) My method filters out false positives detected by the motif scan. 
Motif scan predicts binding sites that do not necessarily correspond to a true physiological binding 
site. My algorithm is inclusive in respect to low affinity sites and uses the ChIP-seq coverage to 
filter out false positives. 
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My method identifies binding sites with high spatial resolution by integrating 
information from both the genome sequence and ChIP-seq coverage. The 
method leverages the information about the genome sequence by means of de 
novo motif discovery (Fig. 2.1C). Specifically, the motif discovery part scans the 
genome sequence for potential binding sites and use them to constraint the 
search space of deconvolution (see subsection 2.5.3). The deconvolution 
process classifies which of the potential sites are true or false positives. Some of 
the potential binding sites predicted by motif discovery are not bound in vivo and 
I refer to them as false positives. Also, some of the true positive sites, i.e. the 
sites that are bound in vivo, are not predicted by motif scan. The proportion of 
false and true positive sites predicted by motif scan depends on a cutoff 
threshold of motif conservation. A good threshold should provide a balance 
between the number of true and false positives. My method takes advantage of 
the ChIP-seq coverage to filter out sites that do not correspond to a true binding 
site while it identifies the true positive sites (Fig. 2.1C). As a consequence, 
BRACIL is able to perform motif scans with a more inclusive cutoff threshold and 
provides a better tradeoff between sensitivity and specificity of binding site 
detection (Fig. 2.1C, see also section 2.5.3). 
2.2 The impulse response 
The quality of the blind-deconvolution process, described in the previous section, 
depends on the model used to represent the impulse response. The impulse 
response represents the physical process that transmits the information of the 
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binding that occurs in vivo to the ChIP-seq coverage (Fig. 2.2A). A qualitative 
explanation for this process has already been reported (Kharchenko et al. 2008; 
Valouev et al. 2008). Accordingly, the impulse response consists of a symmetric 
shape and a peak shift on the coverage of the positive and the negative strand 
(Fig. 2.1A, also Fig. 2.2B and 2.2C). The directionality of the sequencing 
process, occurring in the 5’ to 3’ direction, explains the peak shift. The 
sequencing process provides strand-specific tags, which, in turn, result in a 
measurement of strand-specific coverage. The peak shift occurs because the 
coverage on one side of a binding site is associated with tags for the positive 
strand and the coverage on the other side with tags for the negative strand (Fig. 
2.2B). 
A quantitative explanation for the impulse response originates from the 
position of the DNA edges purified for sequencing. This explanation is derived 
from the steps of the ChIP-seq process. Starting at the shearing step, multiple 
break points split the genome into many DNA fragments. In this context, a break 
point is associated to each edge of a DNA fragment. When immunoprecipitation 
occurs, it purifies the DNA fragments that are bound by the TF under 
investigation for sequencing. At the sequencing step, multiple DNA tags identify 
the purified DNA. Each tag identifies the sequence on one of the edges of a DNA 
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Figure 2.2: BRACIL framework is based on the physical comprehension of the ChIP-seq 
process. (A) Illustration of chromatin immunoprecipitation steps. A DNA representation (blue 
string) contains multiple binding sites (purple shade) that might be bound or not by its 
corresponding transcription factor (purple hexagon shape). The pink dashed boxes highlight a 
DNA fragment that is simultaneously bound by two TFs. This fact motivates the double-binding 
signal. The black dashed box highlights the break point selection caused by immunoprecipitation. 
Many break points (solid dark circles) occur, but only the one, at each edge, that is closest to the 
binding site is selected for sequencing. This indicates that the impulse response follows an 
extreme value distribution (see main text) (B) Detailed representation for the impulse response. 
At each strand (green for the positive strand, pink for the negative strand), the impulse response 
follows a distribution f(x) that represents the distance from the DNA fragment edges to the center 
of the binding sites. The coverage at each strand is separated by a peak shift that is equal to 
twice the distance of binding site center and the maximum of f(x). The strand specific coverage 
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and peak shift is consequence of the directionality of sequencing.  (C) Representation of the 
double-binding signal. At each strand, the impulse response follows the same distribution f(x) 
observed for the single-binding signal. On the positive strand it refers to the binding site closer to 
the 5’ end and on the negative strand it refers to the binding site closer to the 3’ end. This causes 
an additional peak shift equal to the distance between the binding sites. (D) The effect of the 
double-binding signal in the signaling process. A region with two binding sites contains three 
sources of signal: a single-binding signal (solid blue upward arrow) for each binding site and also 
a double-binding signal (dashed blue upward arrow, D-left). The decomposition of the coverage 
into individual impulse responses and the corresponding impulse representation is also shown 
(D-right).  
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fragment. The ChIP-seq coverage is a count of the number of tags aligned at 
each genome position, and thus of the location of the break points. From a  
mathematical point of view, the break points are a random process and the 
immunoprecipitation selects the ones with a minimum distance to the binding 
sites. Thus the impulse response can be modeled as an extreme value 
distribution (Fig. 2.2A, dark highlighted box and Fig. 2.2B). 
The precise solution for the extreme value distribution depends on the 
probability that a break point occurs at some genome position. Let V(x) be the 
probability that a break point occurs up to a distance x from a given binding site 
and assuming that the number of break points follows a Poisson distribution (with 
breaking rate λ), the cumulative distribution function (cdf) for the impulse 
response can be described by the following equation (see section 2.6 for full 
derivation): 
F(x) = 1− e
−λ⋅V (x )
1− e−λ  
[2.1] 
 
A simple mathematical manipulation of Equation 2.1 allows V(x) to be 
predicted from the ChIP-seq data (Equation 2.13). This provides a physical 
interpretation for the properties of DNA shearing. It supports the idea that the TF 
creates a ‘protective region‘ around the DNA it binds (Fig. 2.7). Moreover, if V(x) 
follows an exponential shape, the impulse response can be shown to follow a 
Gumbel distribution (Equation 2.13). A Gumbel distribution describes the impulse 
!!
22!
response with two parameters: one representing the peak shift (µ) and one the 
peak shape (β). Both parameters have a clear physical interpretation. The 
parameter β is associated with the breaking resistance around the binding site 
and µ represents a combination of: TF protection zone, breaking rate and also 
breaking resistance (see section 2.6). 
I also introduce a double-binding signal (Fig. 2.2A, purple highlighted box and 
Fig. 2.2C). After the shearing step, some of the DNA fragments might contain two 
sites that are simultaneously bound. These double bound fragments provide a 
second order impulse response that is centered between both sites. If the break 
points occur independently from each other, the impulse response for the double-
binding signal follows the same shape as the one for the single-binding signal, 
but with an extra peak shift equal to the distance between the binding sites (Fig. 
2.2C). This implies that the coverage at the positive strand refers to the binding 
site closest to the 5’ prime edge and the coverage at the negative strand to the 
site closest to the 3’ edge (Fig. 2.2C). The representation of a region containing 
two binding sites and how its coverage is decomposed is shown in Fig. 2.2D. 
2.3 High-resolution binding site detection 
I first applied my model to obtain binding site detection at high-resolution. In 
order to validate the model, I compared it to a reference set where binding, at 
single nucleotide resolution, has been confirmed by DNA footprint experiments 
(Chauhan et al. 2011). This set contains 47 binding sites within 19 intergenic 
regions for the M. tuberculosis transcription factor DosR. The ChIP-seq data for 
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DosR is taken from a recent study of my current lab about the regulatory network 
of M. tuberculosis (Galagan et al. in press).  
I compared the resolution of the method to the predictions of current state of 
art peak callers (Valouev et al. 2008; Zhang et al. 2008; Wilbanks and Facciotti 
2010; Feng et al. 2011). Peak callers have not been designed to identify multiple 
binding sites inside an enriched region and show a higher variance around the 
precise location when compared to my method (Fig. 2.3A and 2.3B). My method 
was also compared to GEM (Guo et al. 2012), a recent algorithm proposed to 
identify binding sites with high-spatial resolution. Figure 2.3A-B suggests that my 
method performs better. Both my method and GEM use sequence integration to 
improve spatial resolution. However, the signal processing perspective of my 
model is theoretically different than the empirical spatial distribution of reads 
used by GEM and might explain the difference in performance.  
In addition, my method is not specific to a particular peak-caller, but 
complementary. In this sense, my approach proves to be more versatile as it can 
be used in conjunction with the most appropriate peak caller for a specific 
experimental condition. Figure 2.3A illustrates the potential of my method to 
refine the output of peak-callers. It increases the sensitivity of binding site  
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Figure 2.3: BRACIL increases the resolution of binding site detection as well as sensitivity 
and specificity. The performance achieved by using only ChIP-seq coverage (BRACIL-co) is 
improved after motif integration using only single-binding signal (BRACIL-sb) and the best 
performance is achieved when it also considers the double-binding signal (BRACIL-db). A 
summary of the differences between the three version can be found in Table 2.1. In the best 
scenario, BRACIL detects 44/47 of the reference sites (Chauhan et al. 2011). The potential of my 
method to refine the output of peak callers can be seen both in terms of the fraction of sites 
detected (A) as well as the resolution they are detected (B). The green bars (A) represent the 
fraction of sites detected by the corresponding peak caller labeled at the x-axis. The purple bars 
on the top show the additional refinement provided by my method. The different shades in purple 
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represent performance improvement by specific variations of BRACIL. My method is especially 
important for filtering out low conservation motifs that does not represent real binding, as it can be 
seen in the precision and recall (C) and the ROC (D) plots. 
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Figure 2.4: The binding motif can be observed in the sequence that surrounds the 
predicted binding site. The figure depicts the high-resolution of my method. Each row indicates 
the sequence surrounding a predicted motif center. The colors represent a different DNA letter. 
Results are shown for two M. tuberculosis transcription factors: DosR (left) and Kstr (right). A 
small shift at motif center was allowed to improve visualization. Average shift was less than 2bp 
and is visualized by gray colors.  
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Table 2.1:  
BRACIL improves point estimation of binding site detection. This table summarizes the 
performance obtained by different variations of BRACIL and compares it to the performance 
obtained by motif discovery and peak-callers alone. The number of binding sites predicted by 
motif scan depends on a threshold, here represented in terms of the motif p-value. For peak-
callers, I considered the value of the peak-caller with best result. BRACIL-co, BRACIL-sb and 
BRACIL-db vary in terms of the features used for deconvolution. BRACIL-co uses only ChIP-seq 
coverage. Both BRACIL-sb and BRACIL-db integrates ChIP-seq coverage with motif discovery. 
For BRACIL-sb the model considers only the single-binding signal and for BRACIL-db the model 
also considers the double-binding signal. All predictions were constrained to be in a 301 bp 
window around reference binding sites. Similar results were obtained when considering a 251 or 
201 bp window. AUCROC refer to the area under a ROC curve. 
Method True 
positives 
False 
positves 
Missing 
sites 
False positives filtered 
out 
AUCROC 
BRACIL-db 44 5 3 37 0.9420 
BRACIL-sb 40 4 7 38 0.8941 
p-value ≤10-2.5 45 42 2 0 0.8457 
p-value ≤10-3 40 13 7 29 0.8465 
BRACIL-co 24 0 23 42 0.5106 
peak-callers 20 0 27 42 0.4255 
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detection from less than 45% to up to over 91%. In addition, the high sensitivity 
of my method is also accompanied by high specificity (Fig. 2.3C-D). 
The advantages of an integrated model of genome sequence and ChIP-seq 
coverage is summarized in table 2.1. My method takes advantage of the ChIP-
seq coverage to filter out false binding sites that would be detected by using motif 
discovery alone (see section 2.5 and section 2.5.3) and increases the sensitivity 
and specificity of binding site detection (Fig. 2.3C and 2.3D). This effect was 
particularly important in predicting true binding sites with weak evidence of motif 
conservation that would not be predicted otherwise. Moreover, the binding motif 
can be observed in the sequence that surrounds the final set of binding sites 
(Fig. 2.4). My method considers a penalty parameter to avoid overfitting and is 
robust for a large range of values. 
2.4 High-throughput application and orphan regions 
My method was designed with a level of computational efficiency that makes it 
applicable to large data sets, such as ChIP-seq data from large genomes or from 
multiple experiments. The analysis of these data sets was not feasible for the 
previously proposed blind-deconvolution model to study ChIP-seq, csdeconv 
(Wilbanks and Facciotti 2010). A high-throughput application of my method was 
used in a study of ours to map the regulatory network of M. tuberculosis from 
ChIP-seq data (Galagan et al. in press). This study showed that my method 
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Figure 2.5: BRACIL reduces the number of orphan regions while it still filters out false 
binding sites. Orphan regions are regions that are not supported by an instance of a binding 
site, but show highly enriched coverage. The number of orphan regions reduces with a more 
inclusive threshold, such as motif pvalue < 10-2.5, at the cost of increasing the amount of false 
binding sites. The threshold motif p-value < 10-3 is commonly used to provide a balance between 
false positive and true positive. My method allows a more inclusive threshold at the same time it 
uses the ChIPseq coverage to filter out for potential false positives. The fraction of orphan regions 
(A) and the average number of sites per non-orphan regions (B) per ChIP-seq experiments is 
shown for three methods. My method (red line) reduces the number of orphan regions when 
compared to what is identified using a conservative motif threshold (p-value < 10-3, blue line). The 
threshold motif p-value < 10-2.5 (yellow line) is less conservativef and shows the least number of 
orphan regions. The difference in the number of orphan regions predicted by my method and 
motif p-value < 10-2.5 indicates that part of this reduction is not supported by ChIP-seq coverage. 
This is in agreement that a low motif p-value threshold will identify false binding sites. The data 
used for this analysis is taken from a study for the regulatory network of M. tuberculosis (Galagan 
et al. in press) The plot shows only experiments with at least 10 enriched regions. The x-axis is 
sorted according to absolute number of orphan regions detected by my method.  
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Figure 2.6: BRACIL shows high magnitude reproducibility in eukaryote ChIP-seq data. This 
analysis used the benchmarked ChIP-seq data that suggested by Rye et al. (Rye et al. 2011). 
Unfortunately, this benchmark is based only on enriched regions and further work is required to 
obtain a high-resolution benchmark with binding sites mapped at single-nucleotide resolution. The 
results for the transcription factors MAX, NRSF, and SRF are shown in panel A, B, and C, 
respectively. The top of each panel plots the reproducibility of impulse response magnitude 
replicates and in the bottom, the predicted binding motif. The predicted magnitude showed high 
correlation between NRSF and SRF replicates and was not as well correlated for MAX. The 
deconvolution of MAX ChIP-seq data is more challenging because ChIP-seq coverage has low 
abundance and because motif scan predicts an excessive number, including multiple overlapping 
candidates, of potential binding sites. This somewhat ambiguous motif prediction of MAX binding 
sites was also observed in previous report (Pique-Regi et al. 2011). A higher coverage would be 
necessary to evaluate the potential of the deconvolution model in distinguishing the most likely 
binding sites from the large number of binding site candidates and a high-resolution benchmark 
would enhance the evaluation and highlight the precision of my method.  
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estimates binding site locations as well as magnitudes with high reproducibility. 
High reproducibility in terms of impulse response magnitudes has also been 
observed when my method is applied to eukaryotes, as exemplified in Figure 2.6 
for three human transcription factors, Max, NRSF, and SRF, that have been 
recently been defined as a benchmark for peak caller (Rye et al. 2011).  
My method increases the consistency between motif discovery and the 
enriched regions found in the ChIP-seq data. A common feature in ChIP-seq 
analysis is that not all enriched regions contain at least one instance of a binding 
motif (Johnson et al. 2007; Valouev et al. 2008; MacQuarrie et al. 2011). In this 
study, I use the term “orphan regions” to refer to such regions. Different reasons 
might explain the presence of orphan regions. For example, some of them might 
not correspond to a true binding region (Rye et al. 2011), some might not be 
directly bound by the target factor (Valouev et al. 2008), or the motif cutoff 
threshold was not able to capture a low affinity binding site. My method is more 
robust in identifying weak sites because it uses a less conservative cutoff 
threshold. In consequence, it identifies the consistency of binding motif and 
ChIP-seq coverage in regions that otherwise would be classified as orphan 
regions. Moreover, the extant orphan regions predicted by my method are better 
candidates in the search of enriched regions that do not represent a direct 
binding or of enriched regions that are just artifacts of the ChIP-seq technique. 
In the context of orphan regions, I analyzed the results of my method to the 
ChIP-seq data of different TFs from a global study of M. tuberculosis regulatory 
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network that has been conduced by our lab (Galagan et al. in press). For this 
analysis, I considered only the single-binding signal. My method uses a more 
inclusive motif p-value threshold (10-2.5 instead of the commonly used 10-3) that, 
on a global scale, reduces the number of orphan regions by 45% (from 3994 to 
2161), while it still filters out false positives. Over 22% of the orphan regions 
obtained by my method had an instance of a weak motif, but they were filtered 
out by the deconvolution step. The average number of binding sites per regions 
is 1.58 ± 1.64 considering a motif p-value < 10-3 and 1.32 ± 0.91 for my method 
(see Fig. 2.5 for individual experiments). For comparison, an average of 2.95 ± 
2.65 potential binding sites per region was found using motif p-value threshold < 
10-2.5.  
2.5 Formal definition of binding site detection framework 
I model the expected ChIP-seq coverage at a position x as a sum of weighted 
contributions from a number of impulse responses. More specifically, each 
binding site location li emits an impulse response of magnitude mi. The impulse 
response is represented by a function f(x-li;θ) of parameters θ. In my model, f 
follows a Gumbel distribution and theta θ represents the corresponding 
parameters (µ and β, equation 2.11). In summary, the expected coverage at a 
genome position x is computed by the following equation: 
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[2.2] 
 The coverage is strand specific and the indices fw and rv represent, 
respectively, the forward and reverse strands. The total number of binding sites 
is represented by |L| and b(x) represents the background coverage. I assume 
b(x) to be a constant specific to each enriched region. The symmetry in the 
strand specific coverage implies that ffw(x;θ) = frv(-x;θ) = f(x; θ). 
Equation 2.2 assumes that each binding site is an independent source of 
an impulse response. Following, I also consider a second order term, 
represented by the double-binding signal. The magnitude and location of the 
double-binding signal are represented by mi,i+1 and li,i+1, respectively. The index 
indicates that the signal occurs between site i and i+1. The double-binding signal 
also considers di,i+1, the distance between the binding sites and depends on a 
maximum distance limit, d*. The expected coverage at position x is then 
computed as: 
 
 
[2.3] 
E[Cfw (x;M,L,θ )]= b(x)+ mi ⋅ f fw ((x − li );θ )
i
|L|
∑
E[Crv (x;M,L,θ )]= b(x)+ mi ⋅ frv ((x − li ));θ )
i
|L|
∑
E[Cfw (x;M,L,θ )]= b(x)+
mi ⋅ f ((x − li );θ )
i
|L|
∑ + mi,i+1 ⋅ f fw ((x − (li,i+1 −
di,i+1
2 );θ ) ⋅ I(di,i+1 < d
*)
i
|L|−1
∑
E[Crv (x;M,L,θ )]= b(x)+
mi ⋅ f (−(x − li );θ )
i
|L|
∑ + mi,i+1 ⋅ frv ((x − (li,i+1 +
di,i+1
2 ));θ ) ⋅ I(di,i+1 < d
*)
i
|L|−1
∑
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Notice that this representation assumes that L is an ordered set, i.e., li<li+1. 
The term I(S) is an indicator function that takes the value 1 when the condition S 
is true and 0 otherwise. Also, the extra peak shift caused by the double-binding 
signal (section 2.2, Fig. 2.2C) is readily observable by noticing that li,i+1-di,i+1/2 =li 
and li,i+1+di,i+1/2 =li+1. All other terms follow the same definition as in equation 2.2.  
2.5.1 Deconvolution model 
The location and magnitude of the binding sites are extracted from the ChIP-seq 
data using a blind-deconvolution model (Fig. 2.1B-top). The parameters are 
estimated by likelihood maximization of the observed coverage, C, according to 
the following equation: 
 [2.4] 
Assuming that the observed coverage follows a normal distribution around the 
expected value (Equations 2.2 and 2.3), and that the prior P(L,M,θ) can be 
converted into a penalty function, α(r), specific to each enriched region r, the 
likelihood maximization for an enriched region r is equivalent to minimize the 
following objective function: 
 [2.5] 
and a global objective function is given by: 
 [2.6] 
where R represents the set of enriched regions identified by some peak caller. 
argmaxL,M ,θ P(L,M,θ |C) = argmaxL,M ,θ P(C | L,M,θ ) ⋅P(L,M,θ )
objr (L,M,θ ) =α(r)+ (Cfw (x)−E[Cfw (x;M,L,θ )])2 + (Crv (x)−E[Crv (x;M,L,θ )])2
x∈r
∑
obj(L,M,θ ) = objr (L,M,θ )
r∈R
∑
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The objective function is minimized in two steps: 
The ML step: 
 [2.7a] 
and the P step:  
 [2.7b] 
 
The ML step updates the information about the binding sites (location and 
magnitude), while the P step updates the impulse response parameters (θ). Both 
steps are repeated iteratively until convergence. 
This iterative process is computationally expensive when the number of 
enriched regions is large. However, the algorithm reduces to just the ML step if 
the parameters for the impulse response are known. In order to increase the 
computational efficiency, the full algorithm is used only on a subset of the 
enriched regions. The analysis presented in this paper uses the16 most enriched 
regions. This provides an estimate for the impulse response parameters. 
Following, the ML step is used to perform deconvolution in each enriched regions 
independently. 
The penalty parameter, α(r) (equation 2.5), is defined to avoid overfitting, and 
consequently, false positives. It has a slightly different definition when 
deconvolution uses ChIP-seq coverage only or when it also considers motif 
discovery. In the case it uses only ChIP-seq coverage, the penalty function 
(L(i+1),M (i+1) ) = argminL,M obj(L,M,θ (i) )
(θ (i+1) ) = argminθ obj(L(i+1),M (i+1),θ )
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increases linearly with the number of sites detected. The case of sequence-
integrated deconvolution is described in detail in the motif integration section 
(section 2.5.3). 
2.5.2  Motif discovery 
Motif position specific score matrix (PSSM) was obtained using MEME (Bailey et 
al. 2009). The input FASTA file was built using the 101bp sequences that spans 
50bp around each side of the binding site locations predicted by the blind-
deconvolution algorithm using only the coverage information. 
2.5.3  Motif integration 
I used FIMO (Bailey et al. 2009) and the obtained motif PSSM to scan the 
sequence of enriched regions and detect potential binding sites. The potential 
binding sites constrained the space for binding site locations (L in Equation 2.5). 
In this context, the location of an impulse response is restricted to the center of a 
binding motif plus or minus a small window. This window permits deconvolution 
to capture some variance around the precise location of a potential binding site. 
The computational performance is optimized when the locations of the impulse 
response are restricted to the center of a potential binding site, i.e. the window 
size is equal to zero. This assumption simplifies the solution of the objective 
function to a constrained linear least squares problem. 
In the context of motif integration, the shape of the impulse response was 
updated by running the ML and P steps (Equations 2.7a and 2.7b), with locations 
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constrained to a 5bp window around sites with motif p-value < 10-3. This step was 
only performed on a subset of the enriched regions (default is the 16 most 
enriched region) to obtain the parameters for the impulse response. After that, 
deconvolution (ML step) was performed in all regions. In this part, the potential 
binding sites were defined with a more inclusive threshold (motif p-value < 10-2.5) 
and a penalty function was defined to filter out potential false positives. 
The penalty function (α(r), equation 2.5) attributes a higher penalty to weak 
binding sites and a lower penalty to strong ones. If the ideal penalty function has 
a logistic growth proportional to the motif conservation, a binary approximation 
can be used to improve computational performance. In this perspective, I classify 
the potential binding sites as strong or weak sites. The deconvolution was 
performed free of penalty for strong sites and with a linear increasing cost for 
weak sites. I defined α(r)= α0⋅K(r), where K(r) represents the sum of squares of 
the coverage at region r and α0 a constant with values from 0 to 1. Unless 
otherwise stated, my analysis considered α0=0.01.  
Any site with motif p-value (p) in the range of 10-4 <p<10-2.5 was defined to be 
a weak site and any one with p≤10-4 was defined to be a strong site. This is an 
inclusive threshold when compared to other papers (e.g. motif p-value <10-3 
(Jothi et al. 2008; Valouev et al. 2008)).  A site is classified as true only if it 
contributes to deconvolution, i.e. if it has a non zero magnitude after the 
minimization of the objective function. 
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 Finally, binding sites are allowed to emit a double-binding signal if they are 
close to each other up to a distance threshold (50bp by default). The double-
binding signal provides no cost (i.e. no penalty) if it is associated with a strong 
site. This is supported by the strong effect that weak sites have on expression 
when they act in combination with strong sites (Kim and O'Shea 2008; Gertz et 
al. 2009). 
 
2.6 Detailed derivation and physical meaning of the impulse response 
Here I provide a full derivation for the impulse response (Equation 2.1 in the 
main text) based on the fact that it follows an extreme value problem. 
I define as v(x) the probability a break point occurs at a distance x of a 
reference binding site and V (x) = v(i)
i=0
x
∑ the cumulative distribution function 
(cdf), indicating the probability a break point occurs up to a distance x of a 
binding site. The immunoprecipitation step selects the break point, at each edge, 
with the closest distance to a binding site. If V(x) is sampled N times, the cdf 
describing the minimum value out of N samples is represented by the following 
equation: 
V1:N (x) =1− (1−V (x))N  [2.8] 
The number of samples is equivalent to be number of break points that occur 
in a region surrounding the binding site. Since the shearing step occurs at 
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random, N is best described as a stochastic process and the correct cdf that 
describes the impulse response is computed as:  
F(x) = P(N = n | n > 0) ⋅
n=1
∞
∑ V1:N (x)  
[2.9] 
Assuming N follows a Poisson distribution with parameter λ, the Equation 2.9 
can be written as F(x) = e
−λλ n
n!(1− e−λ )V1:N (x)n=1
∞
∑ , and after simplification, it will take 
the form of the Equation 2.1 (main text), which I repeat in the following equation: 
F(x) = 1− e
−λ⋅V (x )
1− e−λ  
[2.10] 
 
2.6.1 Impulse response as a Gumbel distribution. 
It is hard to know the exact distribution for V(x). A precise value might depend 
on different variables: DNA conformation, nucleotide composition, presence of 
ligands, elasticity, the proteins that are bound, the intensity of sonication and 
others. However, assuming V(x) has a truncated exponential shape (say 
V (x)∝ e
x
β ), Equation 2.10 becomes F(x) ≈1− e−e
x+ln(λ )⋅β
β
 and can be 
approximated into a Gumbel distribution: 
F(x) ≈1− e−e
x−µ
β
 
[2.11] 
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The advantage of this assumption is that the parameters of the Gumbel 
distribution provide a physical interpretation for the impulse response. The 
parameter β corresponds to the shape of the impulse response and indicates the 
break resistance around a binding site. The higher the value of β the harder it is 
for a break point to occur near the binding site, suggesting that the transcription 
factor creates a protective region around the site it binds. The parameter µ 
represents half of the peak shift between the coverage of the negative and 
positive strand (see Fig. 2.2B). The physical interpretation for µ depends on the 
Poisson parameter (λ) and also on β, in the form of µ=ln(λ)⋅β. The parameter µ 
also contains, implicitly, the possibility that the best reference for V(x) is not the 
center of a binding site, but some point at the edge outside the region the protein 
binds. In this case, µ=x0 + ln(λ)⋅β, where x0 indicates a region fully protected from 
shearing.  
The impulse response used in the deconvolution process refers to a 
probability distribution function. The derivation showed so far represents the 
cumulative distribution function for the impulse response. The probability density 
function comes from a simple derivative of the cdf, and the impulse response is 
represented in the form:  
f (x) ≈ 1
β
e−e
x+µ
β
 
[2.12] 
The full validation of the assumptions used to derive the impulse response 
into a Gumbel distribution is not part of the scope of this paper. However, the 
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representation of the impulse response in terms of an extreme value problem is 
mathematically compelling and motivates the use of a Gumbel distribution. The 
physical insights of this model are focuses of future research. 
2.6.2 Empirical estimation of V(X) 
 Equation 2.10 (also Equation 2.1) suggests that the probability a break point 
occurs up to a distance x of a binding site, V(x), can be predicted from the ChIP-
seq coverage, according to the following equation:  
 Where Fc(x;x0) represents the empirical cumulative distribution function 
around a binding site that is centered at x0 and is obtained from the ChIP-seq 
coverage. 
An illustrative instance of an empirically measured V(x) is shown in Figure 
2.7. The upward concave shape near the center of the binding site, represented 
by an exponential fit with positive parameters, indicates that DNA shearing is 
harder to occur at a distance close to the binding site (up to around 75bps apart). 
This result is consistent with reports of ultrasound cleavage of DNA, in which 
DNA shearing saturates at small size of DNA fragments (Fukudome et al. 1986), 
and might be consequence of decreasing chance to shear short DNA pieces. An 
alternative explanation is that it might be consequence of a protection region 
around the site a TF binds. 
 
V (x) = − log(1−FC (x; x0 )(1− e
−λ ))
λ
 
[2.13] 
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Figure 2.7: DNA break probability measured based on the ChIP-seq coverage. My model 
suggests that the probability a break point occurs up to a distance x of a binding site (V(x)) can be 
empirically measured from the ChIP-seq coverage (Equation 2.13). The upward concavity (red 
dashed line) in the empirical V(x) (blue solid line) indicates that the probability for a break point to 
occur increases with the distance to the binding site. This might be consequence of a protection 
region around the site a TF binds or because DNA shearing saturates at small size of DNA 
fragments (Fukudome et al. 1986).  
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Chapter 3 
Detecting cooperative interaction from ChIP-seq data 
 
This Chapter describes how the model presented in the previous chapter can be 
used to predict cooperative interaction from the ChIP-seq data. I illustrate how 
the fundamentals of thermodynamics and signal-processing are linked in the 
context of the ChIP-seq analysis. Specifically, the probability of binding to a 
specific site is proportional to the magnitude of the corresponding impulse 
response. Moreover, in order to obtain the secondary term necessary for 
cooperative interaction predictions, I explicitly model a signal that represents the 
probability that two sites are bound simultaneously. Using this framework, I 
describe a statistical test that predicts cooperative interaction from the ChIP-seq 
coverage. Finally, I apply this test in a set of regions known to contain 
cooperative interacting sites and to a set of regions with simulated coverage for 
two non-interacting binding sites. My method was able to discriminate both sets 
and show a promising new opportunity in the ChIP-seq analysis.  
 
Another application of the model described in the previous chapter is in 
identifying cooperative interaction between two contiguous binding sites. 
Cooperative interaction occurs when binding to a site influences the probability of 
binding to another site. Mathematically, cooperative interaction can be assessed 
by comparing the probability that both sites are bound to the probability that each 
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site is independently bound. The following sections in this chapter will formalize 
the definition of  cooperative interaction and show how it can be estimated from 
ChIP-seq data. 
3.1 Formal definition of cooperative interaction 
Before defining the null and the alternative model to test for cooperative 
interaction, I need to define cooperative interaction. Cooperative interaction 
occurs when the binding to two neighboring sites is not independent from each 
other. 
Considering a region with two neighboring sites, four binding 
conformations are possible: (0,0), (0,1), (1,0) and (1,1), where each number 
refers to a binding site and the values 1 and 0 indicate whether it is bound or not. 
This representation allows cooperative interaction to be defined in terms of the 
probability that both sites are simultaneously bound (p1,1) and the probability of 
binding to each site (p1,• = p1,0 + p1,1 and p•,1 = p0,1 + p1,1). The formal definition of 
cooperative interaction is represented in the following equation: 
ω =
p1,1
p1,• ⋅ p•,1
 [3.1] 
In this context, ω=1 indicates that binding is independent and ω≠1 indicates 
cooperative interaction. 
The binding probabilities are associated to the impulse signal magnitudes. 
The rationale for this relationship is described as following. A conformation with 
only one site bound can only emit a single-binding signal, that creates an 
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association between the single binding magnitudes, m1 and m2, to the 
corresponding binding probabilities, p1,0 and p0,1. Similarly, the double-binding 
signal occurs for the conformation that both sites are bound and close to each 
other. This justifies the relationship of the double binding magnitude, m1,2, and 
the double bound probability, p1,1. The magnitude of each signal also depends on 
the probability that the target transcription factor is selected by 
immunoprecipitation, represented by the constant ρ. A single-binding fragment 
contains one TF target and is purified with probability ρ, while a double-binding 
fragment contains two targets and is purified if any of the targets is 
immunoprecipitated, i.e. with probability 1-(1-ρ)2. A summary of the relationship 
between the magnitude of the impulse responses and the probabilities for each 
conformation is described in the following equation: 
m1∝ρ ⋅ (p1,0 )
m2 ∝ρ ⋅ (p0,1)
m1,2 ∝ (1− (1− ρ)2 ⋅ (1−Fs (d1,2 )) ⋅ p1,1
 
[3.2] 
The proportion indicates that the scaling factor between magnitude and 
probability is unknown. The term Fs(d1,2) refers to the probability a double-binding 
fragment can be split into two single-binding fragments. In the representation 
shown in equation 3.2, I assume that when a double bound DNA fragment is split 
in two, the consequent signal would be just some noise in the data, thus, it does 
not represent a single-binding nor a double-binding impulse response.  
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The theoretical derivation of the impulse response (section 2.2 and 2.6) 
indicates that the cumulative distribution function of the impulse response, F(x), 
represents the probability a break point occurs up to a distance x of a binding 
site. If this probability is independent of the binding conformation, the probability 
a double binding fragment is split in two single-binding signal can be computed 
from the impulse response, i.e. Fs(x) = F(x). Assuming that the double binding 
conformation increases the protective area in two closely spaced binding sites, 
the chance a double binding fragment will be split in two reduces, thus 
Fs(x)<<F(x). Approximated values for the impulse response indicates that 
F(x)<0.2 for a binding site distance of 20bps. This implies that Fs(x)<<0.2 and the 
equation 3.2 is simplified to: 
m1 = c ⋅ρ ⋅ p1,0
m2 = c ⋅ρ ⋅ p0,1
m1,2 = c ⋅ (1− (1− ρ)2 ) ⋅ p1,1
 
[3.3] 
Where the constant c was used to transform the proportion into equality. 
The assumption of independent binding causes m1,2 to be a function of m1 
and m2. This constraint disappears in the case of cooperative interaction. Thus, 
the assumption of independent binding is a particular case of the cooperative 
interaction.  
The closed solution for m1,2 as a function of m1 and m2 is shown for two 
extreme cases, assuming low and high immunoprecipitation rate. The solution 
comes from solving equation 3.3 constrained to independent binding (ω=1, 
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equation 3.1) and to the fact that p00+p10+p01+p11=1. A detailed derivation is not 
shown, but the solution is easily achieved using an algorithm that solves systems 
of equations.  
When immunoprecipitation rate is low, ρ≈0 and the term (1- (1-ρ)2) in equation 
3.2 is simplified to 2ρ. Thus, m1,2 is computed as following: 
m1,2 =
−(m1 +m2 ) ⋅ p0,0 + ((m1 +m2 )2 ⋅ (p0,0 )2 + 4m1 ⋅m2 ⋅ (1− p0,0 ) ⋅ p0,0 )1/2
p0,0
 
[3.4a] 
Similarly, when immunoprecipitation rate is high, ρ≈1, the term (1- (1-ρ)2) in 
equation 3.2 is simplified to ρ. Thus, m1,2 is computed as following: 
m1,2 =
−(m1 +m2 ) ⋅ p0,0 + ((m1 +m2 )2 ⋅ (p0,0 )2 + 4m1 ⋅m2 ⋅ (1− p0,0 ) ⋅ p0,0 )1/2
2 ⋅ p0,0
 
[3.4b] 
Notice that m1,2 depends not only on m1 and m2, but also on the probability 
that none of the sites are bound, p0,0. This happens because, as shown in 
equation 3.2, there is no signal in the ChIP-seq coverage with direct 
correspondence to p0,0. 
 The null model, assuming independent binding, is defined from Equations 
3.4a and 3.4b. Thus, the minimization of the objective function (ML step, 
equation 2.7a) is performed such that the magnitude of the double binding signal 
is constrained according to equation 3.4a or 3.4b.  The equations 3.4a and 3.4b 
are also used as a simplified model for cases with more than two binding sites. In 
addition, the probability that none of the sites are bound is unknown, thus the 
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objective function depends on an input parameter p0,0. The objective function for 
the null model is represented as following: 
objr,null;p0,0 = objr (L,M,θ;mi,i+1(mi,mi+1, p0,0 ))  [3.5] 
The term mi,i+1(mi, mi+1, p0,0) indicates that the magnitude of each double binding 
signal is a function of the magnitude of its neighbor sites and of p0,0. 
The magnitude of the double binding signal is unconstrained for the model 
that includes cooperative interaction and follows the representation shown in the 
main text (equation 2.5). The objective function computed for the null and 
alternative model is used in the likelihood ratio test. The assumption of 
independent binding turns the null model a particular case of the alternative 
model, justifying the use of the likelihood ratio test. 
3.2 Statistical test to detect cooperative interaction using ChIP-seq 
A likelihood ratio test is used to detect cooperative interaction. The likelihood 
ratio is defined by: 
D = n ⋅ (log(objnull )− log(objalternative ))  [3.6] 
and follows approximately a Chi-squared distribution with number of degree of 
freedom equal to the number of double-binding impulse responses. The test is 
performed at each specific region. The terms objnull and objalternative represent the 
objective function for the null hypothesis (assuming independent binding) and the 
alternative hypothesis (allowing cooperative interaction). The parameter n 
indicates the number of points used for the fit. Since coverage occurs in both the 
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forward and reverse strands, n is equal to twice the region length. A full 
derivation is shown in the following subsection. 
3.2.1 Detailed derivation of cooperative interaction test 
Here I show how the likelihood ratio test is derived the context of cooperative 
interaction prediction. Let Lnull and Lalternative be the likelihood of the null and the 
alternative models, respectively. The likelihood ratio is defined by a chi-squared 
distribution, of the following parameter: 
D = −2 ⋅ (log(Lnull )− log(Lalternative ))  [3.7] 
The degree of freedom is equal to the number of extra parameters allowed for 
the alternative model when compared to the null model. 
The terms Lnull and Lalternative can be computed from the objective function 
(equation 3.5 and equation 2.5). The assumption that the observed coverage 
follows a normal distribution around the expected value (subsection 2.5.1), brings 
the following relationship: 
L = − n2 log(2π )−
n
2 log(σ
2 )− 12σ 2 obj  
[3.8] 
Where obj represents the objective function and n the number of points used to 
compute it. The likelihood L is maximized when σ2=obj/n. The number n is the 
same for the alternative and null models, thus the parameter D in equation 3.7 is 
computed as following: 
D = n ⋅ (log(objnull )− log(objalternative ))  [3.9] 
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3.3. Simulated set of enriched regions 
A simulated set of enriched regions was created to contain two non-interacting 
binding sites. Each region in this set contained 2 binding sites, separated from 
each other by 20bp. The coverage of each simulated enriched region results 
from two single-binding signals, one for each site, and a double-binding signal in 
between them. Each signal is proportional to the corresponding binding 
conformation. Thus, the magnitude of the single-binding signal at one site is 
proportional to the probability that only this site is bound and the magnitude of 
the double-binding signal is proportional to the probability that both sites are 
bound (Fig. 3.2).  
 To make it more realistic, this simulated set was obtained from the 
coverage empirically observed in the ChIP-seq data. The coverage of a 
simulated enriched region corresponds to the sum of empirical impulse 
responses that represent three signals two of the single-binding type and one of 
the double-binding type. This sum is re-scaled according to the corresponding 
binding probabilities (Fig. 3.2). The empirical impulse response for each single-
binding signal was defined to be 
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Figure 3.1: The feasible space for independent binding. (a) This figure represents the space of 
binding conformation probabilities, for two binding sites, in terms of the probabilities that only one 
of the sites is bound. The space is constrained to p1,0 + p0,1 ≤ 1 (see section 3.1). Independent 
binding is only possible in the range of probabilities indicated by the blue area. This space can be 
solved analytically and is represented by (p0,1 – p1,0)2-2⋅(p0,1 + p1,0) + 1 ≥ 0. Under the assumption 
of independent binding, each point in the blue area determines uniquely the values of p0,0 and 
p1,1. (b) Different points representing independent binding (green markers) were used to create 
the simulated set of enriched regions (see section 3.3). These points were chosen to be 
representative of the feasible space and challenge cooperative detection for different proportions 
of binding conformation (see table 3.1). The solid blue line shows upper boundaries for 
independent binding feasible space, solid red line indicates boundary for probability space 
(p1,0+p0,1=1). The dashed red line indicates that the probability of a single binding conformation is 
10% (i.e. p1,0+p0,1=0.1). The ratio p0,1/p1,0 varies up to three order of magnitudes. 
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Figure 3.2: Schematic representation of simulated enriched region generation. Each region 
was defined to contain two binding sites and the binding sites were assumed to bind 
independently from each other. (a) The theoretical representation of the single-binding and the 
double-binding impulse responses (see sections 2.2 and 2.5, and also equation 2.3). The forward 
and reverse coverage of the double-binding impulse response has a correspondence to each 
single-binding responses. The binding sites are represented by purple squares. The dark and 
light shades indicate if sites are bound or unbound, respectively. (b) An empirical impulse 
response corresponds to the observed coverage, taken from real data, around a region 
containing only one binding site. The empirical double-binding impulse response is simulated 
from the coverage of two single-binding empirical impulse responses, according to model 
represented in (a). The small panels at each plot show an impulse representation for each signal. 
(c) The simulated enriched region is obtained by performing a weighted sum of the empirical 
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impulse responses. The weights are scaled according to the corresponding binding probability. 
The binding probabilities are defined under the constraint of independent binding (see table 3.1). 
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Table 3.1: List of binding conformation probabilities used to create a simulated set of 
enriched regions. This list was chosen to be representative of the feasible space of independent 
binding (see Figure 3.1b). 
P0,0 P1,0 P0,1 P1,1 
0.09 0.10 0.3837 0.4263 
0.09 0.01 0.8100 0.0900 
0.09 0.001 0.8990 0.0100 
0.19 0.10 0.4652 0.2448 
0.19 0.01 0.7600 0.0400 
0.19 0.001 0.8048 0.0042 
0.29 0.10 0.4536 0.1564 
0.29 0.01 0.6767 0.0233 
0.29 0.001 0.7066 0.0024 
0.39 0.10 0.4059 0.1041 
0.39 0.01 0.5850 0.0150 
0.39 0.001 0.6074 0.0016 
0.49 0.10 0.3405 0.0695 
0.49 0.01 0.4900 0.0100 
0.49 0.001 0.5080 0.0010 
0.59 0.10 0.2651 0.0449 
0.59 0.01 0.3933 0.0067 
0.59 0.001 0.4083 0.0007 
0.69 0.10 0.1834 0.0266 
0.69 0.01 0.2957 0.0043 
0.69 0.001 0.3086 0.0004 
0.79 0.10 0.0976 0.0124 
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0.79 0.01 0.1975 0.0025 
0.79 0.001 0.2087 0.0003 
0.89 0.10 0.0090 0.0010 
0.89 0.01 0.0989 0.0011 
0.89 0.001 0.1089 0.0001 
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the observed coverage surrounding a binding site in a region with strong 
evidence of containing only one binding site. A region was considered to have 
only one binding site with strong evidence if it shows low enrichment, passes 
peak caller filter and does not show multiple instances of a binding motif. The 
empirical coverage was normalized so that it would represent an impulse 
response of area equal to one. This normalization is important when the sum of 
the impulse responses is re-scaled according to the corresponding binding 
probabilities (Fig. 3.2). The empirical impulse response for the double-binding 
signal is taken as a mixture of the empirical impulse response for each single-
binding signal. Particularly, the coverage of the forward strand follows the 
corresponding coverage for the impulse response at the binding site closest to 
the 5’ edge. Similarly, the coverage of the reverse strand follows the 
corresponding coverage for the impulse response at the binding site closest to 
the 3’ edge (Fig. 3.2a-b). This is consistent with the double-binding signal 
theoretically modeled in section 2.2 (see also Equation 2.3).  
 I created different sets of simulated enriched regions, each one assuming 
a different probability of binding conformations (see Fig. 3.1). A large range of 
binding conformation probabilities is consistent with independent binding (see 
Fig. 3.1a). The probabilities will define the proportions of each binding signal 
magnitudes that are used to simulate the enriched regions (Fig. 3.2c). A different 
probability will imply a different proportion. I created multiples sets of enriched 
regions, each one assuming a different probability of binding conformation. The 
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binding conformation probabilities were chosen to represent a large range of the 
space of independent binding probabilities (see Fig. 3.1). The conformation 
probabilities used in this analysis are listed in Table 3.1. Each simulated set was 
created with all possible combinations of 5 enriched regions, representing a total 
of 15 simulated enriched regions.  
3.4. Validating cooperative interaction model 
In this section we check the performance of the method of cooperative 
interaction detection, described in section 3.1 and 3.2, in predicting cooperative 
interaction in a reference data set known to contain cooperative interacting sites 
versus a simulated set (section 3.3) defined to contain independently bound 
sites.  
I use a likelihood ratio test to detect cooperative interaction, where the null 
hypothesis assumes independent binding (see 3.2). Under the assumption of 
independent binding, the magnitude of a double-binding impulse response is a 
function of the magnitude of neighboring single-binding impulse responses (see 
3.1, equation 3.4a and 3.4b). This constraint does not occur in the case of 
cooperative interaction. My method is consistent if the probability of rejecting the 
null hypothesis is high for regions with cooperative interaction and relatively 
lower for cases without cooperative interaction. My method was tested on a set 
of experimentally validated cooperative interacting sites for the M. tuberculosis 
transcription factor DosR (Chauhan et al. 2011) and compared to a simulated 
negative control, where binding is known to occur independently. The negative 
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control corresponds to a simulated set of enriched regions, each one containing 
two non-interacting binding sites (section 3.3). This set was created from the 
observed coverage of enriched regions that contains only a single binding site 
(see section 3.3 and Fig. 3.2). The ability of my method in distinguishing 
cooperatively interacting sites from independent binding sites was measured by 
the area under a ROC curve, with value ≈ 0.85 (Fig. 3.3, see also Fig. 3.4 and 
3.5).  
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Figure 3.3: The double-binding signal allows the detection of cooperative interaction from 
the ChIP-seq data. My method (equation 3.6) was able to distinguish regions containing 
cooperative interacting sites from regions containing independent binding sites. A set of regions 
with experimentally validated cooperative interaction was used as a positive control (Chauhan et 
al. 2011). The negative control was obtained from simulation (Fig. 3.1 and 3.2, table 3.1, also see 
section 3.3) (A,B) The p-value output of my method is able to discriminate regions with 
cooperative interaction (solid lines) from regions with independent binding (dashed lines). Each 
dashed-line represents a different simulated set. Each solid-line assumes a different value for the 
probability of non-binding conformation (see section 3.1 and 3.2). The probability of non-binding 
conformation is a necessary input to compute statistical p-value. Independent of the value for 
non-binding conformation, my method discriminates the data well. A good discriminative power 
occurs even for the most conservative case (highlighted by the dashed-red and solid-blue lines). 
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(C, D) The overall performance of my method is measured in terms of true versus false positive 
rate. The solid blue line represents the results from plots A or B. The dashed red line shows what 
is expected by chance. The area under the curve (auc) measures the discriminative power of the 
method. All results support my method. In addition, the method is robust when performance 
evaluation is specific to each probability of non-binding conformation (Fig. 3.4 and 3.5). The 
results at the left (A, C) and right (B, D) panels are obtained assuming low or high 
immunoprecipitation rate, respectively. 
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Figure 3.4: Detection of cooperative interaction is robust to an exhaustive range of the non-
binding conformation probability. The non-binding conformation probability (p0,0) can not be 
extracted from the ChIP-seq data and is a necessary input to model independent binding 
(equations S4a-b and 3.5). The performance of my method is presented in terms of the true 
positive rate as a function of the false positive rate. The true positive set corresponds to regions 
experimentally validated to contain cooperative interaction and the false positive set indicates 
simulated regions containing independent binding (section 3.3). (A-I) Each plot illustrates the 
performance assuming a fixed value of p0,0. This panel assumes that immunoprecipitation occurs 
at low rates (equation 3.4a).  All the results corroborate my method.   
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Figure 3.5: Similar to Figure 3.4, however, it assumes that immunoprecipitation occurs at 
high rate (equation 3.4b). All the results corroborate my method. 
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Chapter 4 
Implications in the study of gene regulatory network 
 
This chapter discusses the implications of my method in the study of gene 
regulation. My method provides a multi-disciplinary approach that contributes 
both to the theoretical understanding of the ChIP-seq process as well as to new 
applications. The physically motivated representation of a binding site signal 
suggests the possibility of studying physical properties of DNA shearing from the 
ChIP-seq data.The high-resolution identification of binding site detection as well 
as cooperative interaction suggests the potential of deciphering biological circuits 
from ChIP-seq data. 
 
I have utilized a blind deconvolution approach (Lun et al. 2009) to develop a 
novel method that improves computational efficiency, identifies binding sites at 
high spatial resolution, and detects cooperative interactions using ChIP-Seq 
data. Both resolution and cooperative interaction play key roles in the 
mechanistic understanding of a gene regulatory network (Oppenheim et al. 2005; 
Kim and O'Shea 2008; Segal and Widom 2009; Giorgetti et al. 2010). My method 
is complementary to peak-callers and provides a new step that improves the 
current pipelines of ChIP-seq analysis (Furey 2012). The gains of my model are 
consequences of a theoretically refined model of ChIP-seq that is based on a 
signaling process perspective integrated with physical and thermodynamic 
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concepts. To the best of my knowledge, this is the first method that integrates 
genome information (via motif discovery) and ChIP-seq coverage to extract 
regulatory details of an enriched region as a modular complement of peak 
callers. In addition, my method predicts cooperative interactions, proposing a 
novel outcome from ChIP-seq analysis. Cooperative interaction prediction is 
possible due to explicitly modeling of the double-binding signal (Fig. 2.1a, pink 
dashed box, Fig. 2.2c). Also, my results highlight the importance of the double-
binding signal to improve sensitivity and specificity of binding site detection. 
Moreover, the simplification of the blind-deconvolution algorithm enables its 
application to large datasets, a feature not possible in my previous model 
csdeconv (Lun et al. 2009; Wilbanks and Facciotti 2010). 
The proof of principle of my model, both in terms of single-nucleotide 
resolution binding site detection as well as cooperative interaction predictions, 
was validated in a data set of 47 binding sites that lie in 19 regulatory regions for 
the M. tuberculosis TF DosR (Chauhan et al. 2011). The fact that this dataset is 
based on high-resolution experiments motivates my choice and avoids the 
subjective bias that can be introduced by manually curated benchmarks. In 
addition, high-quality ChIP-seq coverage is available for the testing TF, with 
signal to noise ratio in enriched regions up to a few hundred times the median 
coverage (Galagan et al. in press).  For the cooperative interaction test, it is 
difficult to obtain a reference data set that assures sites are bound 
independently. Therefore, the most appropriate negative control was a simulated 
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set of enriched regions, in which sites are bound independently, by designation. 
In order to estimate to what extent my results are generalizable and to find its 
limitations, a high-resolution dataset would be necessary. For example, one 
limitation of my analysis is that it requires deeper coverage per regions than what 
is necessary for just peak identification. The impulse response signals 
degenerate in regions with low coverage and that makes it harder to discriminate 
the sites that are most likely to represent true physiological binding from a 
multiple sites candidates. In further studies, a high-resolution dataset could clarify 
the accuracy of my method in the analysis of ChIP-seq data. 
My analysis proposes a relationship of the impulse response to the physical 
properties of DNA shearing (see Sup. Text S1). This relationship is potentially 
useful in identifying the conditions that improve the resolution of ChIP-seq data 
experimentally. The resolution of ChIP-seq is limited by the size of DNA 
fragments (Rhee and Pugh 2011) and a more detailed understanding of the 
physical properties of DNA shearing could guide experiments to obtain smaller 
DNA fragments. Thus, my method might be useful to optimize ChiP-seq 
protocols and experimentally improve the resolution of ChIP-seq.  
The next step of my analysis is to explore the biological insights provided by a 
high-resolution map of the gene regulatory network. The functional impact of 
transcription factors on gene regulation depends on the affinity and precise 
location of the binding sites and on the interactions between such sites 
(Oppenheim et al. 2005; Zinzen et al. 2006; Kim and O'Shea 2008; Segal et al. 
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2008; Lu et al. 2009; He et al. 2010). Also, the importance of a high-resolution 
mapping of binding sites and cooperative interactions to control cell phenotypes 
can be exemplified by specific regulatory circuits, such as the well-studied lac 
operon and the lambda switch (Oppenheim et al. 2005; Yaniv 2011). In the case 
of the lambda switch, the circuit that decides whether a bacterial infection caused 
by the λ-phage will be at the lytic or lysogenic state is tuned by precise affinity, 
location and cooperative interaction involving two transcription factors (cro and 
cl) and three binding sites (OR1, OR2, OR3) (Oppenheim et al. 2005).  A high-
resolution map of binding regulatory network should expand the potential of using 
ChIP-seq data to identify regulatory circuits. I expect that my method will help to 
obtain biologically-meaningful regulatory insights from the ChIP-seq data. 
A high-resolution map, as proposed by my method, should improve models 
that integrate the regulatory network with other cell processes. The integration of 
the regulatory network with other sources of `omics` data has been shown to 
improve prediction of high-throughput experiments, such as growth phenotyping 
and gene expression (Covert et al. 2004). A current challenge of systems biology 
is to integrate diverse components that contribute to cell function into cell-scale 
models (Freddolino and Tavazoie 2012; Karr et al. 2012). A recent effort divides 
the M. genitalus cell into 28 submodules, including transcriptional regulation, to 
provide the first full systems biology model of a cell (Karr et al. 2012). Integrated 
models are able to generate experimentally testable hypotheses and original 
explanations for the functioning of a cell (Covert et al. 2004; Freddolino and 
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Tavazoie 2012; Karr et al. 2012). The quality of cell-scale models depends on the 
mathematical comprehension of the system and also on the development of 
computationally efficient algorithms (Freddolino and Tavazoie 2012). A refined 
map of the gene regulatory network is strategically important due to its upstream 
position in simplified cell-scale models that represent the cascade effect of 
regulation in gene expression, translation and cell activity (Covert et al. 2004; 
Feist and Palsson 2008; Thiele et al. 2009). Thus, my method contributes not 
only to improving the quality of a regulatory network itself, but also to any 
process downstream of gene regulation that contributes to cell-scale models.  
The biological insights that can be extracted from high-throughput biological 
data depend on the methods and tools available for data analysis. In a time in 
which a variety of methods to improve the identification of enriched regions have 
been proposed, my work expands the boundaries of ChIP-seq analysis by 
focusing on each enriched region individually.my work exploits 
a multidisciplinary approach that links concepts from signal processing, 
thermodynamics, and statistics to construct methods of data analysis that provide 
original biological insights. I expect that the thermodynamics understanding of 
regulatory regions, as provided bymy work, will be insightful to guide hypothesis-
driven experiments and elucidate mechanisms of individual regulatory circuits 
forming a regulatory network. Finally, I believe the model presented will be useful 
in deciphering biological meaning out of the growing number of available ChIP-
seq data sets. 
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Part II 
Resistance attenuation strategies to fight antibiotic resistant infection 
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Chapter 5 
Background on alternatives to fight drug resistance 
 
This chapter provides an overview about the alarming situation caused by the 
increasing incidence of drug resistant pathogens and describes some recent 
advances in the field, such as the discovery of conditions that select against 
antibiotic resistance. It also provides a short review of the literature on strategies 
to fight drug resistance. 
 
Drug resistance is an important problem during infection treatment, 
particularly in intensive care units (Snitkin et al. 2011). Cases of resistance have 
been described in infections caused by different types of pathogens, such as 
viruses, bacteria, fungi and protozoa (Ghannoum and Rice 1999; Klokouzas et 
al. 2003; Gubareva 2004; Welch et al. 2007) and the increasing incidence has 
made resistance a major public health issue (Klevens et al. 2007). This fact can 
be exemplified by, but it is not exclusive to, infections caused by the methicillin-
resistant Staphylococcus aureus (MRSA), whose incidence rate has almost 
doubled (city of Atlanta) or tripled (city of Baltimore) in a period of three years, 
from 2002 to 2005 (Klevens et al. 2007). The relevance of those numbers is 
evident when compared to other infectious diseases. The number of MRSA 
infection cases was about twice and 30 times the numbers for S. pneumonia and 
H. influenza, respectively, in the calendar year of 2005 and was associated with 
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about 18000 deaths (Klevens et al. 2007). Also, MRSA is associated with over 
20% of S. aureus infections in Europe (Control 2010). This alarming situation 
highlights the need for alternatives to reduce the incidence of resistance. Two 
common potential strategies for this purpose are drug restriction and multiple-
drug therapy. However more work is required to determine the potential 
effectiveness of these strategies to reduce or fight drug resistance and a 
quantitative understanding of their mechanisms in both the single-host and host-
population level. 
Drug restriction consists of suspending a determined class of antibiotics 
for some period of time. It is based on the principle that the absence of selective 
pressure will drive the extinction of a gene from the population (Li and Nei 1977). 
In the presence of antibiotic selection, a plasmid of resistance will improve 
bacterial fitness and will increase in frequency. However, the same plasmid 
brings no advantage, or even a slight disadvantage, when no antibiotic treatment 
is applied. Based on this, if the drug restriction is long enough, resistance can be 
controlled. For example, an early study on drug restriction reported positive 
results using this therapy in the host-population level (Quale et al. 1996). The 
authors observed that six months of Vancomycin restriction was followed by a 
reduction in the proportion of resistant bacteria from 47% to 15%. 
A special case of restriction is drug cycling, in which restrictions to specific 
classes of drugs are alternated over some time interval. A review on the topic 
identified only four references rigorously investigating drug cycling (Brown and 
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Nathwani 2005). Three of them reported cycling to be efficient to reduce 
incidence of resistance and one did not find any statistical significance. They also 
reported lack of standard procedures, which makes it hard to obtain a conclusive 
evaluation of policies. A parallel review was less stringent and observed that 
thirteen out of fourteen studies related to drug cycling reported positive results, 
such as decrease of either resistance, infection rate or mortality rate, while only 
one reported purely negative results (Masterton 2005). Subsequent studies 
reported positive outcomes for drug cycling (Bonten and Weinstein 2006; Kollef 
2006; Martínez et al. 2006; Cadena et al. 2007; Martinez 2007; Francetić et al. 
2008; Hedrick et al. 2008). While one case reported a combination of positive 
and negative results (Cadena et al. 2007), and another discussed drawbacks of 
this approach (Kollef 2006), all of them agreed that more research is needed to 
identify useful  strategies to combat resistance. 
Another option to deal with drug resistance is using multi-drug therapy. 
The properties of drug combinations have been studied for more than 70 years 
(Bliss 1939; Yeh and Kishony 2007). The nature of drug interactions can be 
classified in two main groups: synergistic and antagonistic. An interaction is 
classified as synergistic (antagonistic) if the combined use of two drugs increases 
(decreases) the activity, with respect to a null expectation based on individual 
drug effects (Yeh et al. 2006). In using drug combinations for therapeutic 
purposes, most research until recently has been focused on synergistic 
interactions (Greco et al. 1995; Hegreness et al. 2008; Yeh et al. 2009; Ankomah 
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and Levin 2012). Drug synergy reduces the amount of drug necessary to reach 
the same activity, consequently reducing costs (Hegreness et al. 2008). 
However, new studies have shown that synergistically interacting drugs tend to 
increase the rates of drug resistance, indicating, instead, that it would be useful 
to pursue the potential role of antagonistic interactions in affecting the evolution 
of resistance (Hegreness et al. 2008; Michel et al. 2008; Bollenbach et al. 2009; 
Torella et al. 2010). 
Resistant strains would not be so alarming if we were able to control them. 
In order to do so, one would have to find conditions (called antiR) in which 
sensitive strains are able to grow faster than resistant ones. Under these 
conditions, resistant strains would have a selective disadvantage and decrease 
in population size. The antiR conditions can be applied to attenuate resistance, 
turning an infection susceptible to antibiotic treatment. The effectiveness of this 
strategy depends on a precise timing schedule for the application of antiR and 
antibiotic treatment. 
The existence of antiR conditions have been demonstrated by 
experimental measurements (Chait et al. 2007; Palmer et al. 2010). Chait and 
colleagues used suppressive interaction to favor the growth of a wild type, 
sensitive strain over the growth of a resistant one (Chait et al. 2007). 
Suppressive interactions are a special case of antagonism, and occur when the 
combined effect of two drugs is weaker than the effect of each drug individually. 
A suppressive drug attenuates the effect of an active drug in the sensitive strain, 
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but not in the one carrying the genes for resistance to the suppressive drug. 
Thus, it creates a condition that favors the growth of sensitive strains. 
A second antiR mechanism is possible when resistance is acquired 
through the use of efflux pumps (Palmer et al. 2010). This machinery keeps the 
antibiotic outside the cell and is activated by the presence of the antibiotic. It is 
an expensive process, in which the antibiotic is actively transported against its 
gradient of concentration at expenditure of free energy. Modifications caused by 
chemical decay may cause an antibiotic to be no longer effective, while 
maintaining its capacity to activate the genes for resistance. Under these 
conditions, the modified antibiotic is not effective and the activation of the efflux 
pumps is not associated with any benefit for the bacteria. Thus, it only increases 
the cost of carrying and expressing the genes for resistance, favoring growth of 
sensitive strains. 
In spite of the growing knowledge about antibiotic resistance, there is still 
not a standard way to control it. The use of drug combinations can lead to multi-
resistant strains (Cantón et al. 2003; Kollef 2005; Dijkshoorn et al. 2007; Koul et 
al. 2011). Specific strategies to turn antiR conditions into therapeutic plans have 
not been proposed yet. Drug restriction is not a well-established intervention, with 
only few studies available on the topic (Kollef 2005; Masterton 2005). In the case 
of cycling, lack of standard procedures and arbitrary definition of cycle duration 
are central issues (Brown and Nathwani 2005; Masterton 2005; Kollef 2006), 
making strategies inconclusive. Mathematical models could help to improve 
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strategies. However, most models (Bonhoeffer et al. 1997; Bergstrom et al. 2004; 
Kouyos et al. 2011) predict antimicrobial cycling not to be helpful to reduce 
resistance while most experimental investigation suggests benefits for cycling in 
conflict with most experimental reports (Masterton 2005). Such divergence 
encourages the search for the principles necessary to develop accurate models. 
In the next two chapters, I talk about single-host and host-population strategies to 
fight antibiotic resistance. Chapter 6 uses a previously described mathematical 
single-host model of infection dynamics (D'Agata et al. 2008) to simulate the 
effect of anti-resistance treatment in the fight of antibiotic resistance. This 
analysis suggests that a multiple treatment therapy that uses the sequential 
application of anti-resistance treatment followed by antibiotic treatment can 
effectively fight resistance infection. Moreover, my analysis suggests a 
quantitative estimation of the time, tclear, anti-resistance treatment should be 
applied until a resistant infection would become sensitive to antibiotic treatment. I 
find that tclear is inversely proportional to a constant that describes the speed of 
resistance attenuation, the resistance-decaying rate and that this constant 
depends only on three key parameters: the pathogen division rate, the rate of 
plasmid loss and the difference in growth rate between sensitive and resistant 
strains. Chapter 7 is built up on the idea that the abundance of resistant 
pathogens decays over time and expand it to host-population models of infection. 
The resistance-decaying rate suggests a transition between resistant to sensitive 
pathogen. Explicitly modeling this transition can drastically change the outcome 
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predicted by mathematical models, as illustrated by a modified version of the 
model proposed by Bonhoeffer and Colleagues(Bonhoeffer et al. 1997). 
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Chapter 6 
A time scheduled therapy can successfully fight resistant infection 
 
Previous chapter reviewed some recent reports that describe conditions that 
select against antibiotic resistance (antiR contitions). In this chapter, I use a 
mathematical model of infection dynamics and immunity to show how a precisely 
timed combination of different treatments (no drugs, antibiotic and antiR) can 
defeat resistant strains. Based on this model, I estimate treatment schedules that 
would lead to a complete elimination of both sensitive and resistant strains. In 
particular, I obtained an expression that describes the time necessary to turn a 
resistant infection into sensitive (tclear). This time depends on the rates of 
pathogen division, growth and plasmid loss. Finally, I estimated tclear using 
available empirical data and found that the rate of resistance loss increases up to 
15 times under antiR treatment compared to a regime of no treatment. 
 
 
6.1 Mathematical model of infection dynamics 
My current work builds upon a previous model of bacterial infection and 
immune response, originally proposed to identify strategies to limit the 
emergence of antimicrobial-resistant bacterial strains (D'Agata et al. 2008). The 
pathogens are composed by sensitive (represented by the subscript S) and 
resistant (represented by the subscript R) strains. The abundance of pathogens, 
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B = BS + BR, is limited to a carrying capacity λ·κ (Smith and Holt 1996; Lipsitch et 
al. 2000; Dall'Antonia et al. 2005), giving rise to a logistic growth. The growth 
rate, λS or λR, is the difference between the division (δ) and the mortality (µ) rate. 
The model also considers the effect of the immune system, represented by the 
number of phagocytes (P) and their killing rate (γ). The presence of the immune 
system effectively translates into a threshold of pathogen abundance, above 
which an infection starts (Imran and Smith 2007). The model also assumes that 
the genes for resistance are carried by mobile genetic elements (see also 
discussion in Chapter 8). The resistance-carrying mobile genetic elements can 
be transferred to a sensitive strain, due to horizontal gene transfer, at a rate τ, 
and be lost during replication, with a probability ρ (Tenover 2006). This text 
commonly represents the properties of resistance transfer and loss of mobile 
genetic elements referring to a plasmid. An illustration of the model and 
parameters is shown in Figure 6.1A. Mathematically, the model is described by 
the following differential equations: 
 
[6.1] 
  
dBS
dt = λSBS (t)(1−
B(t)
λSκ
)−γ PP+B(t) BS (t)−τ
BS (t)BR (t)
B(t) +δR
ρ
2 BR (t)
dBR
dt = λRBR (t)(1−
B(t)
λRκ
)
logistic growth
  
−γ
P
P+B(t) BR (t)
immune systemresponse
  
+τ
BS (t)BR (t)
B(t)
recombination
  
−δR
ρ
2 BR (t)
plasmid loss
  
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Figure 6.1: Illustration of the infection dynamics model and of an underexplored 
opportunity to fight resistance. (A) Schematic representation of the main dynamical transitions 
based on the model from (D'Agata et al. 2008). The arrows represent the possible fates of the 
populations of sensitive and resistant pathogen strains. Horizontal gene transfer (rate τ) and 
plasmid loss (rate ρ) are the mechanisms responsible for interconverting between sensitive and 
resistant strains. The use of an antibiotic can reduce the sensitive population, but is not effective 
against the resistant one. Conversely, the cost of carrying a plasmid causes a reduction of the 
resistant population in the absence of antibiotic use. Also, both strains are susceptible to immune 
system killing. The principles of infection dynamics can be used to optimize infection treatments. 
(B) Schematic representation of the current state of infection treatment and the under-explored 
opportunity studies in this research. Regular antibiotic is effective against infection caused by the 
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sensitive strain, but is not effective against infection with high abundance of resistant pathogens 
(B-top). Here I show that an effective control of the infection can be obtained by initially treating 
against the resistant strain (antiR condition) (Chait et al. 2007; Palmer et al. 2010) and 
subsequently applying antibiotic treatment (B-bottom).   
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The values for the parameters used in Equation 6.1 are described in Table 6.1. 
The different conditions described in this paper (no treatment, antibiotic treatment 
and antiR) are distinguished by different values of mortality rate. The analyses 
performed in this paper are obtained by assuming a specific fixed value for each 
parameter. This assumption makes it easier to understand the model principles 
and does not affect the conclusions of my analysis. A sensitivity analysis shows 
that my results are robust to a varying range of parameters (section 6.5 and Fig. 
6.6). 
 
6.1.1 Model intuition 
The model describes an infection by predicting the dynamical changes in 
the population of invasive pathogen. If the population is low, the immune system 
is able to control the infection. When the population is beyond the immune 
system capacity, the infection needs to be controlled by antibiotic therapy (Fig. 
6.2A,B). However, an infection will not be cured if therapy is interrupted before 
pathogen load is sufficiently reduced (Fig. 6.2B) or if the pathogen population is 
resistant to antibiotic (Fig. 6.2D). Also, time delay in antibiotic application can 
indicate whether antibiotic therapy will lead to a successful treatment (Fig. 6.2C)  
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Table  6.1: 
Description of variables used in the infection dynamics model (Equation 6.1). ). Values are 
chosen according to the original reference (D'Agata et al. 2008), unless indicated otherwise in the 
text. For the carrying capacity I used a value that is an order of magnitude lower relative to the 
above reference. This modification is consistent with empirical evidences (Smith and Holt 1996; 
Lipsitch et al. 2000; Dall'Antonia et al. 2005) and does not affect the main properties of the model. 
Symbol Interpretation Default value Units 
λ Growth rate δ-µ day  
δ Division rate 2.7726 day  
µ1 Mortality rate 0 day  
κ λκ: Carrying capacity 1014/2.772610!" 2.7726 
- 
γ Killing rate of phagocytes 33.6038 day  
P Total number of phagocytes 332711 - 
τ Rate plasmid is acquired  day  
ρ Probability plasmid is lost 0.4 day  
  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 mortality rate varied according to treatment conditions (no treatment, antibiotic, antiR) and 
pathogen strain (sensitive or resistance), with values, respectively to each treatment conditions: 
µS= 0, 4 or 1 for the sensitive strain and µR= 0, 0 or 3 for the resistant strain. 
2 In parallel with Biology classes, I took many mathematics and physics related classes, such 
1−
1−
1−
1−
310− 1−
1−
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Figure 6.2: General properties of the infection dynamics models. A treatment is effective 
when total pathogen population is reduced to bellow the dashed line and not effective otherwise. 
Antibiotic treatment is effective when pathogen abundance has a low fraction of resistance. 
Panels (A, B) illustrates the intuitive effect of different lengths of antibiotic treatment in an 
infection caused exclusively by the sensitive strain (blue continuous line). The parameters used in 
this analysis does not affect the qualitative behavior depicted in original model (D'Agata et al. 
2008). A 9 days-long antibiotic treatment (green-shaded region) can reduce infection until the 
immune system is able to control it (A). The same infection is predicted to persist if treatment is 
interrupted after 6 days (B). Panels C-D simulated infection dynamics in a mixed population of 
sensitive (blue continuous line) and resistant (red dashed line) strains. Immediate antibiotic 
treatment can lead to effective treatment (C). However, for the same initial condition shown in (C), 
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the abundance of pathogens increases after a 3 days delay in antibiotic use and antibiotic 
treatment is ineffective (D). The initial abundance of sensitive pathogen is 108 for all panels and 
the initial abundance of resistant pathogen is 102 in panel C-D and null for panels A-B. 
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or not (Fig. 6.2D). More details about the model can be seen in the original paper 
(D'Agata et al. 2008). 
6.2  Treatment against resistant infection 
              I used the model of Equation 6.1 to predict optimal strategies for healing 
infections that involve strains resistant to a single antibiotic. This is performed by 
estimating the outcomes of a therapy based on the application of antiR and 
antibiotic treatment with different time schedules (Fig. 6.1B). Antibiotic usage 
reduces the population of sensitive pathogens while at the same time favoring 
the resistant ones. If the abundance of the resistant population is too high, 
antibiotic treatment is ineffective. I explore whether an appropriate timing of the 
antiR condition (Chait et al. 2007; Palmer et al. 2010) could give rise to 
alternative avenues to combat resistance.  
I studied the effect of an antiR treatment in the infection dynamics and 
how it could help to fight resistant infection. The application of an antiR treatment 
attenuates the abundance of resistant pathogens (Fig. 6.3). Interestingly, the 
intensity of the resistance attenuation increases when the abundance of sensitive 
pathogen is close to carrying capacity. This indicates a change in fitness when 
both strains have to compete for resources. This phenomenon suggests that 
competition for resources might also direct resistance attenuation under no  
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Figure 6.3: Resistance attenuation is boosted when population of sensitive pathogen is 
close to carrying capacity. This figure shows infection dynamics of both resistant (dashed red 
line) and sensitive (solid blue line) pathogens under antiR treatment (purple shade). The intensity 
that abundance of resistant pathogen decreases is relatively weak when sensitive pathogen 
population is far from carrying capacity (time t<8 days), but is strengthened when the population 
of sensitive pathogen is close to carrying capacity. 
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treatment conditions. I simulated infection dynamics when no treatment is applied 
and observed that the stability of the genes for resistance (represented by the 
constant ρ in equation 6.1) as well as the parameters related to growth rate play 
a key role in resistance attenuation when the sensitive population is close to 
carrying capacity (Fig. 6.4). 
My goal is to explore the potential of resistance attenuation as an 
alternative treatment to fight resistant infection. For this purpose, I simulated 
infection dynamics under different treatment schedules (Fig. 6.5). Resistance 
attenuation can be exploited to reduce the population of resistant pathogen to 
low levels, turning antibiotic therapy effective. The higher the intensity of 
resistance attenuation, the faster the abundance of resistant pathogen decays. 
An antiR condition increases the intensity of resistance attenuation and causes a 
resistant infection to become susceptible to antibiotic treatment in a shorted time. 
Figure 6.5 simulates a case that the strong resistance attenuation caused by 
antiR treatment leads into an effective treatment that would not be achievable by 
the weak attenuation obtained by suspending antibiotic use. This result illustrates 
the potential of antiR conditions to accelerate resistance attenuation.  
Surprisingly, the results of my simulations show that the abundance of 
sensitive pathogen can increase under antibiotic treatment (Fig. 6.5B). This 
interesting phenomenon predicts that under a simple assumption that resistance 
can be lost, a highly abundance of sensitive pathogen would spontaneously rise 
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Figure 6.4: Saturated abundance of sensitive pathogen attenuates resistance in the 
absence of antibiotic treatment. The pathogen growth is affected when total abundance of 
pathogen is close to carrying capacity, indicating fitness change when both strains have to 
compete for resources. Under this saturated conditions, both the probability of plasmid loss (A) 
and the growth rate (B) play key roles on resistance attenuation. (A) The intensity of resistance 
attenuation increases with the probability of plasmid loss. Left and right panels show simulation 
results for ρ=0.4 and ρ=0.2, respectively. (B) The intensity of resistance attenuation increases 
with the difference in growth rate between both strains. In this analysis, I set up the probability of 
resistance loss to be equal to zero to highlight only the effects of growth rate. The left panel 
shows a case that both sensitive and resistant strains have the same growth rate. In this case, 
both strains can coexist with high population abundance. In the right panel, I defined a cost for 
resistance that reduced their growth rate from 2.77 to 2. The abundance of the resistant pathogen 
decreases over time when the abundance of the sensitive pathogen is saturated. The intensity of 
resistance attenuation is proportional to the difference in growth rate. Unless otherwise 
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mentioned, all parameters used in this analysis correspond to default values described in table 
6.1 for no treatment condition. 
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Figure 6.5: AntiR treatment boosts resistance attenuation and leads into a successful 
therapy that fight resistant infection. Both antibiotic suspension (no treatment) and antiR 
treatment can reduce the abundance of resistant pathogens. However, this reduction is greater 
under antiR treatment. This figures illustrates the potential advantage of an antiR treatment in 
fighting a resistant infection. When no treatment is applied, the fraction of resistant population 
slowly decreases (A and B, t=[16:36]) and it is followed by an ineffective antibiotic treatment. In 
(B), the resistance attenuation is faster due to treatment against resistance (antiR, purple-shaded 
area), and leads to an effective antibiotic treatment (t>36). The black dotted line indicates 
reference position in the y axis for pathogen abundance equal to a single individual. The initial 
abundance of both sensitive and resistant pathogens is 109. 
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from a high load of resistant pathogen. This result might be useful to study the 
mechanisms that cause resistance attenuation.  
The schematic representation of an effective or ineffective treatment can 
be visualized by a phase plane representation (Fig. 6.6). A phase plane shows 
the direction of pathogen growth according to the abundance of sensitive and 
resistant strains. In my schematic representation, a specific treatment can lead to 
two possible outcomes, represented by two attracting points. The first, that I call 
attractor 1, indicates that the infection is healed and the second, attractor 2, 
indicates the infection is established and the treatment is not successful. In this 
analysis, I use the terms region of infection control to refer to the region of 
pathogen abundance that leads towards healed infection and region of invasive 
infection to refer to the region of pathogen abundance that leads towards an 
established infection (attractor 2).  
The region of infection control and the position of attractor 2 can 
summarize the qualitative outcome of an infection treatment. Starting with the 
region of infection control, it coincides with the immune-system control (Fig. 6.6A) 
under no treatment condition and is extended beyond immune-system control 
under antibiotic or antiR treatment. An antibiotic treatment expands the region of 
infection control towards saturated infection caused by sensitive pathogens (Fig. 
6.6B) and an antiR treatment briefly expands the region of infection control 
towards a higher abundant resistant infection (Fig. 6.6C). Note that, under the 
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Figure 6.6: Schematic representation of infection dynamics depicts success or failure of 
infection treatment. Each panel shows a schematic representation of infection dynamics under 
different type of treatment. A successful treatment reduces the total pathogen abundance and 
directs infection towards the origin (attractor 1). An ineffective treatment is not able to control 
pathogen growth and at pathogen abundance grows towards attractor 2. The areas with dark and 
light shades represent the regions of pathogen abundance where treatment is effective and 
ineffective, respectively. (A) When no treatment is performed, the immune-system is able to 
control infection at low pathogen abundance. In case the infection is established, pathogen 
abundance converges towards a high sensitive population. (B) Antibiotic treatment extends the 
region of pathogen abundance where infection can be controlled and moves the position of 
attractor 2 towards a highly resistant infection. Note that the top right corner of the infection 
control region indicates the maximum abundance of resistant pathogen that guarantees an 
effective antibiotic treatment. (C) An antiR treatment extends the region of pathogen abundance 
where infection can be controlled towards the population of resistant pathogen. However, in this 
conservative representation, this extension is still limited to relatively small pathogen abundance. 
Note that none of the three options of treatment would be successful to treat infection in all range 
of pathogen populations. However, it predicts that an effective treatment would be possible for all 
range of pathogen population in a multi-treatment representation (see figure 6.7). 
Antibiotic treatment
attractor 1:
infection healed
attractor 2:
highly resistant 
infection
re
si
st
an
t p
at
ho
ge
n
ab
un
da
nc
e 
(lo
g 
sc
al
e)
Sensitive pathogen
abundance (log scale)
re
si
st
an
t p
at
ho
ge
n
ab
un
da
nc
e 
(lo
g 
sc
al
e)
No treatment
attractor 1:
infection healed
attractor 2:
satured infection
Sensitive pathogen
 abundance (log scale)
re
si
st
an
t p
at
ho
ge
n
ab
un
da
nc
e 
(lo
g 
sc
al
e)
AntiR treatment
attractor 1:
infection healed
attractor 2:
satured infection
Sensitive pathogen
 abundance (log scale)
A B C
established infectionestablished infection established infection
controled
infection
controled
infection
controled
infection
!!
104!
conservative parameters used for this analysis, the region of infection control 
caused by an antiR treatment does not reach the boundaries of a saturated 
infection. Also, the position of attractor 2 varies according to treatment. It is 
positioned at highly sensitive saturated infection in case of no treatment or antiR 
treatment and at a highly resistant infection in case of antibiotic treatment. 
According to this schematic representation, no single treatment would be 
effective to treat infection towards all range of pathogen population. 
A multi-treatment therapy could heal infection towards a full range of 
resistant and sensitive pathogen abundance. The infection dynamics for a multi-
treatment therapy can be visualized by plotting the phase plane for each 
individual treatment in a tri-dimensional representation (Fig. 6.7). This 
representation helps to choose the correct strategy to combat infection according 
to pathogen abundance. It also helps to visualize necessary conditions for an 
effective treatment. In particular, an effective treatment for a full range of 
pathogen populations requires that the antibiotic treatment is effective even if the 
abundance of sensitive pathogens is at carrying capacity (see section 6.5 and 
Fig. 6.6). Also, an interesting medically relevant outcome of this sensitivity 
analysis is that it provides a potential explanation for the prevalence of high-
resistant infection in immunosuppressed patients (Osman et al. 1992; Jiang et al. 
2011) (see section 6.5).  
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Figure 6.7: Schematic representation of a phase space shows possible paths for an 
effective therapy. A phase space shows the growth direction for different size of the resistant 
and sensitive populations (x and y axis respectively) upon different types of treatments (different 
planes on the z axis). The dark shade in each plane represents the area in which the population 
of pathogen has negative growth (i.e. infection is under control). In this phase space I display a 
specific trajectory representative of a therapy that successfully controls resistant pathogens. Each 
treatment condition is represented as a different plane: no treatment (bottom plane, gray), 
antibiotic (middle plane, green), antiR (top plane, purple). For the bottom and top planes, the dark 
shaded area coincides with the population threshold controlled by the immune system. Variations 
in the parameters for the immune system would cause an extension or contraction of the dark 
area, without affecting major conclusions from this analysis (see also section 6.5 and Fig. 6.9). 
The use of antibiotic extends the range of control, allowing the cure of infections caused by 
sensitive pathogens. No single treatment is able to provide cure in all population ranges. 
However, this can be achieved using multiple treatment therapy. The points (p1, ..., p5) illustrate 
an effective path (which is the same shown in Fig. 6.5B).  
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6.3 Estimating time to lose resistance  
An optimal treatment depends on the precise timing of the application of 
antibiotic and antiR conditions. If the infection is already sensitive, antibiotic 
treatment should be used from the beginning of therapy. On the other hand, if the 
infection is resistant, antiR should be applied first in order to reduce the load of 
resistant pathogen. When the abundance of resistance is low enough, the 
infection becomes sensitive and an effective treatment can be achieved after 
antibiotic application.  
The optimal strategy to combat a resistant infection will depend on how 
the resistant population varies over time. For example, assume that, at a given 
time t, a patient is infected by a given population of resistant pathogen BR(t).  
Under antibiotic treatment, the pathogen carrying the plasmid for resistance will 
increase in frequency. However, in the absence of antibiotic selection, the cost 
associated with the plasmid will cause the frequency of the resistant strain to 
decrease over time (Fig. 6.5A,B). What is particularly noteworthy is that under 
certain conditions (Fig. 6.5B) the resistant population can decrease to a level that 
is low enough, such that the immune system and the antibiotic are able to 
completely eliminate the pathogens. As shown under no treatment or antiR 
condition (Fig. 6.5B) and demonstrated analytically (Appendix 6A, Equation 6.4 
and 6A.5), the decrease in abundance of resistant pathogen can be modeled by 
a linear function, providing the following phenomenological equation:  
 [6.2] logBR (t) = −a ⋅ t + logB0
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where a indicates the rate at which resistance is attenuated (resistance-decaying 
rate) and B0 the abundance of resistant pathogen at a reference time. The 
resistance-decaying rate is associated with the cost of resistance and its value 
increases under antiR conditions. 
The expression shown in Equation 6.2 allows an estimation of the time to 
lose resistance. To compute this time, it is important to consider the maximum 
abundance of resistant pathogen that guarantees an effective antibiotic treatment 
(which I call h0). It is hard to find a closed solution for h0 in terms of the model 
parameters; but this value can be estimated numerically and be visualized in the 
phase plane representation (Fig. 6.6B). In addition, a suboptimal estimation of h0 
satisfies the requirement for a conservative analysis. In the most conservative 
scenario, this threshold corresponds to less than a single resistant pathogen. 
From this estimate, one can evaluate the time necessary to turn the pathogen 
population sensitive to antibiotic treatment (Equation 6.2). In particular, by 
imposing that the abundance of resistance population should be less than the 
threshold h0, in the form log BR < log h0, one obtains:  
 [6.3] 
Note that tclear is inversely proportional to the resistance-decaying rate. 
Applying antiR conditions will increase the resistance-decaying rate, 
consequently decreasing tclear (Fig. 6.5). 
tclear =
log B0h0
a
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An analytical approximation derived from the model (see appendix 6A) 
can be used to estimate the resistance-decaying rate and is summarized by the 
following equation:  
 [6.4] 
where Δλ = λS - λR is the difference in growth rate of sensitive and 
resistant strains. ∆λ≈0 when no treatment is applied and it increases under antiR 
conditions. The parameters δR and ρ are considered intrinsic to the system 
(D'Agata et al. 2008), but strategies on how to manipulate them might be a topic 
of future research. 
 
6.4  Resistance-decaying rate estimated from real data. 
The applicability of the outlined strategy to fight resistance depends on the 
ability to realistically estimate the resistance-decaying rate (Equation 6.4). 
Experimental measurements of the ρ and δR parameters can be obtained using 
the method described in (Gill et al. 2009), while the parameter ∆λ can be 
measured as shown in (Hegreness et al. 2006).  In particular, Gill et al. (Gill et al. 
2009) use quantitative real time PCR to measure plasmid counts and a 
mathematical model to estimate the rate of plasmid loss and in vivo growth and 
death rate, yielding estimates of ρ and δR. Hegreness et al. (Hegreness et al. 
2006), conversely, use fluorescence markers to measure differential growth rate 
between resistant/sensitive strains. Starting from an even population, the 
a ≈ δR
ρ
2 +Δλ
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intensity of each marker measures the ratio of the abundance of each strain, i.e. 
.  
Empirical data for an antiR condition was obtained from (Chait et al. 
2007). The authors measured the ratio of doxycycline-sensitive to doxycycline-
resistance Escherichia coli after 24 hours under control and antiR treatment, 
which was 1.4 and 150, respectively. From those values, I obtain ∆λctrl = 0.34d-1 
and ∆λantiR = 5.01d
-1, where the index indicates, respectively, control and antiR 
conditions.  
Using the values of ∆λctrl and ∆λantiR, I can compute the resistance-
decaying rate (Equation 6.4) and estimate tclear (Equation 6.3) for different values 
of plasmid loss rate. I estimate that resistance attenuation, measured in terms of 
tclear, is up to 15 times faster under antiR conditions when compared to control 
conditions (Fig. 6.8). Moreover, resistance attenuation depends on whether the 
variation in growth rate is caused by increasing mortality or division rate (see also 
section 6B).  
  
eλSt
eλRt = e
Δλt
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Figure 6.8: Resistance attenuation is influenced by the nature of AntiR treatment and 
plasmid loss rate. Both the nature of the antiR treatment (whether bactericidal or bacteriostatic, 
see appendix section 6B) and the rate of plasmid loss influence the dynamics of resistance 
attenuation. I illustrate the resistance decaying rate (A) and tclear (B) as a function of the rate of 
plasmid loss and the nature of treatment. At low rates of plasmid loss, antiR treatment increases 
the resistance attenuation in about 15 times, independently of the nature of antiR treatment. 
Values are estimated according to data published in (Chait et al. 2007).  
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6.5. Sensitivity analysis  
 The qualitative results described in this chapter are robust to a wide range 
of parameters. In this section, I show how the parameters for growth rate and for 
the immune system affect the outcome of my analysis. Two representative 
parameters, the sensitive strain mortality rate, mS, and the number of phagocyte 
cells, P, are chosen for this purpose. Varying the mortality rate provides a similar 
behavior for what would be observed by varying the division rate. A similar 
association links the effects of varying the number of phagocytes to varying the 
phagocyte-killing rate. The standard values that define the antibiotic conditions, 
as represented in table 6.1, are shown as a reference for the sensitivity analysis 
comparison.  
 Results of this sensitivity analysis are shown in Figure 6.9. One main 
result of this analysis is that tuning of the parameters mentioned above (µS, and 
P) affects the boundaries of the pathogen abundance region in which infection 
can be successfully treated (Fig. 6.7 and 6.9). Increasing the mortality rate of the 
sensitive strain (µS) increases the region of resistant pathogen abundance that 
can be contained in a successful treatment. Notice that this abundance is limited 
by the immune-system capacity (Fig. 6.9A). Conversely, decreasing the mortality 
rate will shrink the area of this treatable region. At low mortality rate, the 
presence of a single resistant cell is, in principle, enough to cause antibiotic 
treatment not to be effective for an infection saturated with sensitivity strain (Fig. 
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6.9C, arrow path). At very low value, the efficacy of an antibiotic treatment 
reduces to the immune-system control threshold.  
 Changing the number of phagocytes (P) affects the top edge boundaries 
for a successful treatment, thus affecting the threshold for the immune-system 
control and also the abundance of resistant pathogen that can be contained in a 
successful treatment (Fig. 6.9B). By increasing (decreasing) the number of 
phagocytes, the population area for an effective treatment tends to expand 
(shrink). This sensitivity analysis also provides a potential explanation for the 
observed increased cases of resistance in immunosuppressed patients (Osman 
et al. 1992; Jiang et al. 2011). In particular, one can see that the boundary for the 
pathogen population representing a treatable region is reduced for 
immunosuppressed patients. Below a certain threshold of P (and for a pathogen 
population near the carrying capacity) the antibiotic treatable area becomes null. 
Thus, the presence of even a single resistant pathogen cell would be enough to 
drive a saturated population of sensitive strains towards a high-resistant infection 
(Fig. 6.9C, arrow path). 
 As shown in Figure 6.9D, this sensitivity analysis can also be used to 
estimate the possible effects that pharmacokinetics and pharmacodynamics (e.g. 
time-dependent drug concentration in the patient’s body during upon a single 
dose of antibiotic) could have on the global treatment plan.   
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Figure 6.9: Sensitivity analysis of antibiotic treatment effectiveness is illustrated by a 
schematic phase plane representation. This figure follows the same representation used for 
the antibiotic plane shown in Figure 6.5. The dark shaded areas represent regions of the 
pathogen population that are susceptible to antibiotic treatment, which I refer to as treatable 
region. For panel (A) and (B), these areas are represented for the reference values, as from table 
6.1. Dashed lines represent the boundary edges of the treatable region for different parameter 
values. The intersection at the y-axis indicates the population limit for immune-system control. P0 
and µ0 indicate reference values, according to table 6.1. (A) Increasing the mortality rate of 
sensitive strains, µS, will expand the treatable region. Notice that the immune-system threshold 
limits the expansion for the abundance of resistant pathogen. This is visualized by observing that 
the dark shaded area expands horizontally, but not vertically. Reducing the values of µS will 
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shrink the treatable area. At very low mortality rate, it will converge towards the limits for immune-
system control.  (B) Expansion or contraction of the treatable region as a function of the number 
of Phagocytes, P. (B-C) Notice that at low values of P, the boundary of the treatable region does 
not touch the right side edge of the figure. This indicates the treatable region contracts to a level 
below the carrying capacity. In this case, under antibiotic treatment, the presence of a single 
resistant pathogen cell will be enough to drive highly abundant sensitive population towards high 
resistance (C, dashed arrow). (D) Therapy strategies should consider how drug concentration 
varies under antibiotic treatment. The treatable region will vary according to µmin and µmax, the 
minimum and maximum values of µS during antibiotic treatment. The varying area is represented 
by vertical hatched area. A conservative strategy should consider the values of µmin to plan a 
successful antibiotic treatment. 
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Appendix 
6A Analytical derivation of the resistance-decaying rate 
The parameters to compute the resistant decaying rate (a in Equation 6.2, 
Equation 6.3, also illustrated in Fig. 6.5) can be mathematically derived from 
Equation 6.1. First, let's consider the part related to logistic growth. If the 
pathogen population is near saturation level, i.e., B(t)=BS(t)+BR(t) = λSκ, then the 
corresponding parts in Equations 6.1 reduce to: 
dBS
dt logistic = λSBS (t)−
B(t)
κ
BS (t) = 0
dBR
dt logistic = λSBR (t)−
B(t)
κ
BR (t)−ΔλBR (t) = −ΔλBR (t)
 
 
[6A.1] 
 
where ∆λ = λS - λR. 
At this regime, using the known parameter, I have B(t) ≈ 1014 and γP < 
108. In turn, these values imply that immune system response will be close to 0, 
i.e.  
γ
P
P+B(t) BS (t)<10
−6BS (t)
γ
P
P+B(t) BR (t)<10
−6BR (t)
 
 
[6A.2] 
 
Under these conditions, the sensitive population will be close to the total 
population, i.e., . Thus, variation in population can be approximated 
by:  
)()( tBtBS ≈
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dBS
dt = −τ
BS (t)BR (t)
B(t) +δR
ρ
2 BR (t) ≈ BR (t)(−τ +δR
ρ
2 )
dBR
dt = τ
BS (t)BR (t)
B(t) −δR
ρ
2 BR (t)−ΔλBR (t) ≈ BR (t)(τ −δR
ρ
2 −Δλ)
 
 
[6A.3] 
 
Since t is much smaller than δR
ρ
2  and Δλ , and 
BR (t)
BS (t)
≈ 0 , I can simplify 
Equation 6A.3 and finally get: 
d
dt log(BS (t)) ≈
BR (t)
BS (t)
(δR
ρ
2 ) ≈ 0
d
dt log(BR (t))
' ≈ −δR
ρ
2 −Δλ
 
 
[6A.4] 
 
The resistance decaying rate, i.e. the coefficient a of Equation 6.2, can be 
taken from Equation s4 and it will be equal to  
a ≈ δR
ρ
2 +Δλ  
[6A.5] 
 
Equation 6A.5 is also represented in section 6.3, labeled as equation 6.4. It is 
repeated here to provide better comprehension of the text. The coefficient a can 
be substituted in Equation 6.3 to estimate tclear. The quality of this analytical 
approximation was compared to measurements from the simulations shown in 
Fig. 6.5, with estimated value at least 96% of the exact value. 
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6B The mechanism of action of antiR treatment affects the resistance-
decaying rate. 
The estimated value for the resistance decaying rate a (Equation 6.4), and 
therefore of the time to lose resistance tclear (see Equation 6.3), depends on 
whether antiR treatment affects the growth by changing the division or the 
mortality rate, i.e. on whether a drug is bacteriostatic or bactericidal respectively. 
A purely bactericidal mechanism affects growth rate by increasing mortality rate 
(µR), while the effect of a purely bacteriostatic treatment reduces division rate 
(δR). Hence the dependence on the type of antibiotic can be seen by a careful 
analysis of Equation 6.4, which can be rewritten more explicitly as a ≈ δR⋅ρ/2 + λS 
- (δR-µR).  
In particular, at low enough rates of plasmid loss (ρ), the first term in 
Equation 6.4 becomes negligible, and the resistance decaying rate will depend 
only on the net difference between division and mortality rates (i.e. the directly 
measurable growth rate), irrespective of whether the antibiotic is bacteriostatic or 
bactericidal. On the contrary, at high rates of plasmid loss, the division rate of 
resistant bacteria (δR) has to be explicitly taken into account through the first term 
of Equation 6.4.  
The method developed in (Hegreness et al. 2006) can measure ∆λ, i.e. 
the growth rate, under different conditions. Since δR is relevant to compute the 
resistance-decaying rate, it is important to state if the reduction on the value of λ 
is caused by increasing µ (bactericidal) or by decreasing δ (bacteriostatic). A drug 
!!
118!
might not be purely bacteriostatic or purely bactericidal. In such cases, 
resistance-decaying rate would assume a value between the pure 
bacteriostatical and pure bactericidal cases.  
Experimental measurement of the rate of plasmid loss (ρ) and in vivo 
division rate (δR) can be obtained according to the method developed by Gill et 
al. (Gill et al. 2009). In this method, ρ is measured by quantitative real time PCR. 
The value of δR can be estimated from a mathematical model that considers in 
vivo measurement of growth rate and plasmid loss. 
My model predicts that at high rates of plasmid loss, purely bactericidal 
treatments are more effective in combating resistance. However, the nature of 
treatment mechanism is not relevant if the plasmid loss is a rare event. Details 
about it are shown in Fig. 6.8. 
 
References: 
Chait R, Craney A, Kishony R. 2007. Antibiotic interactions that select against 
resistance. Nature 446(7136): 668-671. 
D'Agata E, Dupont-Rouzeyrol M, Magal P, Olivier D, Ruan S. 2008. The Impact 
of Different Antibiotic Regimens on the Emergence of Antimicrobial-
Resistant Bacteria. PLoS ONE 3(12): e4036. 
Dall'Antonia M, Coen PG, Wilks M, Whiley A, Millar M. 2005. Competition 
between methicillin-sensitive and -resistant Staphylococcus aureus in the 
anterior nares. The Journal of hospital infection 61(1): 62-67. 
!!
119!
Gill W, Harik N, Whiddon M, Liao R, Mittler J, Sherman D. 2009. A replication 
clock for Mycobacterium tuberculosis. Nature medicine 15(2): 211-214. 
Hegreness M, Shoresh N, Hartl D, Kishony R. 2006. An Equivalence Principle for 
the Incorporation of Favorable Mutations in Asexual Populations. Science 
311(5767): 1615-1617. 
Imran M, Smith H. 2007. The Dynamics of Bacterial Infection , Innate Immune 
Response , and Antibiotic Treatment. Discrete and Continuous Dynamical 
Systems - B 8: 127 - 143. 
Jiang J-R, Yen S-Y, Wang J-Y. 2011. Increased prevalence of primary drug-
resistant pulmonary tuberculosis in immunocompromised patients. 
Respirology (Carlton, Vic) 16: 308-313. 
Lipsitch M, Dykes JK, Johnson SE, Ades EW, King J, Briles DE, Carlone GM. 
2000. Competition among Streptococcus pneumoniae for intranasal 
colonization in a mouse model. Vaccine 18(25): 2895-2901. 
Osman AS, Jennings FW, Holmes PH. 1992. The rapid development of drug-
resistance by Trypanosoma evansi in immunosuppressed mice. Acta 
Tropica 50: 249-257. 
Palmer A, Angelino E, Kishony R. 2010. Chemical decay of an antibiotic inverts 
selection for resistance. Nature chemical biology 6(2): 105-107. 
Smith VH, Holt RD. 1996. Resource competition and within-host disease 
dynamics. Trends in ecology & evolution 11(9): 386-389. 
!!
120!
Tenover FC. 2006. Mechanisms of antimicrobial resistance in bacteria. The 
American journal of medicine 119: S3-10; discussion S62-70. 
 
  
!!
121!
Chapter 7 
Optimal antimicrobial usage predicted by a host-population model is 
strongly dependent on a transition related to the resistance-decaying rate. 
 
In the previous chapter, I introduced the resistance-decaying rate; a constant that 
represents how fast the abundance of resistant pathogen is reduced in a single-
host model. In this chapter, I explore the concept of resistance-decaying rate into 
host-population models of infection. Those models represent sick and healthy 
individual and how infection can be healed or transferred among them. In such 
models, sick individuals can carry a resistant or non-resistant infection and 
transmit it to health individuals. Host-population models are useful to predict 
optimal policies, such as drug-cycling, drug-mixing or drug-combination, that 
would reduce the incidence of drug-resistance. The concept of resistance-
decaying rate indicates that a resistant pathogen can lose resistance and 
become sensitive. I characterize the possibility of resistance loss as transition 
states from resistant to sensitive infection and applied it in a modified version of a 
previously published host-population model of infection and show that it predicts 
a completely different outcome by considering that resistant infection may lose 
resistance. 
 
The idea behind resistance attenuation, discussed in the previous chapter, 
can be expanded to host population models and used to develop strategies for 
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drug restriction. The analysis in the previous chapter proposes that, at the single 
host level, the rate at which a resistant pathogen becomes sensitive to an 
antibiotic treatment is proportional to the resistance-decaying rate. This suggests 
that, at a host-population level and in the absence of antibiotic treatment, a drug 
associated with a faster resistance-decaying rate should lose resistance in a 
shorter time and that optimal cycling duration would be inversely proportional to 
experimental measurements of the resistance-decaying rate (Fig. 7.1).  
In addition, the principle of resistance attenuation might be useful in the 
debate of optimal policies that would reduce the incidence of resistant infection. 
For example, the model proposed by Bonhoeffer et al. (Bonhoeffer et al. 1997) 
recognizes the possibility that sensitive pathogens could acquire resistance 
(parameter s in equation 7.1, or equation 6.3 in (Bonhoeffer et al. 1997)), but 
there is no parameter explicitly representing the possibility of resistance loss. 
Rather, in the original model, the cost of resistance is associated with a faster 
recovering rate. I performed a simulation of the Bonhoeffer et al. model with 
default parameters and compared it to a modified version that represents 
transitions from resistant to sensitive strains (see section 7.1 and Fig. 7.2) My 
analysis shows that the addition of a term that explicitly refers to resistance 
attenuation can yield a drastically different conclusion when compared to the  
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Figure 7.1: Drug cycling policies may be potentially improved by experimental 
measurement of the resistance-decaying rate. I illustrate a case with two classes of drugs. 
The time span in which drugs A and B are restricted is represented, schematically and 
respectively, by the red and blue interval. The current policies, so far reported, do not rely on 
quantitative theoretical support to define cycling duration. My analysis suggests that resistance 
abundance is attenuated according to a resistance-decaying rate (Equation 6.4). Thus, it is 
reasonable to consider that experimental measurements of the resistance-decaying rate could be 
useful to motivate drug specific cycling duration.  
  
Current cycling policies: 
Quantitative motivated schedules: time 
Restrict drug A 
Restrict drug B 
time 
Restrict drug A
Restrict drug B
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original model (Fig. 7.3), i.e. that cycling is the optimal strategy and that cycling 
period can be optimized (Fig. 7.3D and 7.3H).  
7.1 Resistance-loss may change conclusion of host-population model of 
infection dynamics  
Bonhoeffer et al. proposed a mathematical model to describe the benefit 
of different drug therapies against resistant bacteria (Bonhoeffer et al. 1997). The 
model describes the dynamics of infection in a host population. In their model, 
individuals can be contaminated by four different bacteria strains, characterized 
based on their sensitivity or resistance to two drugs (a and b). The following 
equation describes my modified version of the model (where I highlight in red the 
modified part) (see Fig. 7.2): 
 
 
 
 
 
 
[7.1] 
 The variables for the original model are: 
dx
dt
= d x b( yi )+
i (w,a,b,ab)
( riyi )
i (w,a,b,ab)
+
+h(1 q) fabyw + h(1 s)( fa + fb )yw +
+ fayb + fbya + fab(ya + yb )
dyw
dt
= (bx c rw h( fa + fb + fab ))yw + (ya pa2w + yb pb2w )
dya
dt
= (bx c ra h( fb + fab ))ya + hsfayw + ( ya pa2w + yab pab2a )
dyb
dt
= (bx c rb h( fa + fab ))yb + hsfbyw + ( yb pb2w + yab pab2b )
dyab
dt
= (bx c rab )yab + hs( fab(ya + yb )+ fayb + fbya )+ qhfabyw yab(pab2a + pab2b )
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Figure 7.2: Schematic representation of modified host-population model of infection. The 
modified model (Equation 7.1 and 7.2.) allows the possibility of resistance to be lost. This model 
classifies infection in four types: wild type, a-resistant, b-resistant and a,b-resistant. In this figure, 
each type of infection is represented as yw, ya, yb, ya,b , respectively. The original model 
considered only the possibility of acquiring resistance (black arrows), however, the cost of 
resistance, measured in the form of the resistance-decaying rate, motivates the modified model 
(red arrows). 
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 : uninfected population. 
: indexes for wild type, a-resistant, b-resistant and ab resistant 
strains respectively. 
: abundance of hosts infected with pathogen i in (wt, a, b, ab). 
 : rate of uninfected host entering the system. 
 : death rate of uninfected population. 
 : transmission rate. 
: recovery rate from infection of type i in (wt, a, b, ab). 
 : maximum recovery rate under antibiotic treatment. 
 : fraction of patients treated with antibiotic i in (wt, a, b, ab). 
 : death rate of infected patients. 
 : fraction of hosts that becomes resistant when treated with single drug. 
 : fraction of hosts, which becomes resistant when treated with both 
drugs simultaneously 
The new model considers specific distinct paths to lose resistance, whose 
rates are represented by the terms pa2w, pb2w, pab2a and pab2b (see Fig. 7.2), 
hence adding reversibility to the paths for acquiring resistance in the original 
model. The single-host analysis wpresented in the chapter 6 suggests that, in  
x
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q
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Figure 7.3: Modified host-population model provides different conclusions on the 
strategies to combat resistance. In (Bonhoeffer et al. 1997), the authors conclude that drug mix 
and drug combination outperforms drug cycling strategy, however, different conclusions can be 
reached by the modified model (see also Fig. 7.2). The gain of therapy is measured by the 
increasing amount of uninfected patients x (shown as <G> in each plot). The original model 
suggests that drug combination provides the best strategy, while the modified model suggest 
potential gain for cycling. In addition, cycling periods can be improved to increase gain (compare 
A vs D or E vs H). Cycling 5/5: drugs a and b are alternated at every 5 time units; Drugmix 0.5: of 
patients receive treatment with drug a and 0.5 with drug b; Drug combination: all patients receive 
both drugs; Cycling 1/1: drugs a and b are alternated at every 1 time unit. Parameters are taken 
according to the original publication (Bonhoeffer et al. 1997), with rw=0, ra = rb = 0.1, rab = 0.2. 
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the absence of antibiotic use, the resistance to antibiotic is lost according to the 
resistance-decaying rate (Equation 6.4). Here, I explore the implications of this 
individual-host resistance-decaying rate to the dynamics of infections at the 
population level. The resistance decaying rate, as derived in the chapter 6, 
suggests that resistance is lost exponentially in the pathogen, thus I assume that 
the new rates of population-level loss of resistance pa2w, pb2w, pab2a and pab2b are 
exponentially decreasing functions of the corresponding fractions of infected 
hosts as defined in the following equation: 
 
pa2w = e−k ( fa+ fab )
pb2w = e−k ( fb+ fab )
pab2a = e−k ( fa+ fab )
pab2b = e−k ( fb+ fab )
 
 
 
 
[7.2] 
 
Using this modified model, I studied the effect of different drug treatment 
strategies (cycling, mixing, combination) on a population of hosts, and compared 
results with the original Bonhoeffer population model. The original model 
indicates that drug cycling favors double resistant infection (Fig. 7.3A). However, 
a different conclusion can be achieved when the rate of plasmid loss is 
considered (Fig. 7.3E). Also, the modified model shows that drug cycling can 
outperform drug mixing and drug combination (Fig. 7.3A-C and Fig. 7.3D-F). In 
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addition, in support to the conclusions illustrated in Fig. 7.1, I show that better 
control of resistance can be achieved by improving cycling period. 
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Chapter 8 
The relevance of resistance attenuation in future works that search for 
strategies to fight resistance. 
 
This chapter discusses about the implications and limitations of an anti-
resistance therapy in terms of resistance attenuation. It describes conditions 
necessary for a potential application in single-host treatment and how the 
principle of resistance attenuation could help in the debate of optimal strategies 
to reduce the risk of untreatable infection in host-population models. Chapter 6 
suggested that a few experimentally measurable parameters can describe the 
intensity of resistance attenuation. I expect that experimental measurements will 
help to improve model fundamentals and that better models will provide more 
accurate insights into policies to combat the incidence of drug resistance.  
 
The results in chapter 6 illustrates a case where an infection could be 
cured based on the specific timing of two treatments: antibiotic and antiR (a 
condition that preferentially reduces the population of strains resistant to a target 
antibiotic) (Fig. 6.5). It shows that the optimal duration of the antiR administration 
(tclear) depends on the resistance-decaying rate, a constant that can be estimated 
from experimentally measurable parameters (Chait et al. 2007; Gill et al. 2009). 
From the knowledge of tclear, we are able to define a time-scheduled therapy, in 
which anti-resistance treatment precedes antibiotic treatment according to some 
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time schedule. In the absence of antiR conditions, resistance attenuation can 
also occur by suspending antibiotic use. 
A primary potential application of a time-scheduled therapy is to treat 
persistent infections, in which resistance turns antibiotic treatment alone 
unsuccessful (Leung and Katial 2008; Hannan et al. 2010; Høiby et al. 2010). For 
example, long-term antibiotic treatment has been reported likely not useful to 
treat chronic sinusitis (Leung and Katial 2008). Strategies taking advantage of 
antiR conditions will be especially useful under conditions in which tclear is small 
relative to the timescale of infection progress. This could be especially interesting 
for resistance related to chronic infections. By mapping infections on the phase 
space representation (Fig.6.7 and 6.9) one could discriminate between antibiotic 
treatments likely to be effective versus treatments predicted to lead to a resistant 
infection (section 6.5 and Fig. 6.9). This mapping could be achieved, for example 
by sequencing samples and evaluating the abundance of the different strains.  
The challenge of obtaining resistance attenuation might vary according to 
the type of resistance. Antibiotic suspension would make a resistant infection 
become sensitive to antibiotic treatment when resistance brings a fitness cost or 
when resistance loss is a frequent event. Also, antiR conditions would boost 
resistance attenuation or make it possible to fight resistance in cases antibiotic 
suspension would not be enough. An application of resistance attenuation, 
however, should be more challenging if a specific antiR condition is not available. 
This analysis does not focus in describing an immediate and practical protocol to 
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fight resistant infection. The objective of this analysis is in searching for simple 
principles that would generate insights into resistance attenuation and that could 
eventually direct into strategies to fight a resistant infection. 
The insight obtainable through the present analysis is limited by the 
capacity to effectively implement antiR conditions, and by the assumptions made 
by the model (Equation 1). The antiR condition obtained through the use of a 
suppressive interacting drug occurs only at a limited range of drug 
concentrations, which might not be easily controllable for treatment application. 
In addition, the presented analysis does not consider the possibility that the 
pathogen can adapt to this treatment by developing a second resistance. 
Furthermore, the resistance attenuation, affecting tclear, is strengthened when the 
population of pathogens is close to its carrying capacity (Fig 6.3). This evidence 
of resource competition was also shown to be an important factor to selection of 
high-resistant strains (Pena-Miller et al. 2013). As a consequence, my analysis 
suggests that the population of non-pathogens, by influencing the carrying 
capacity (Smith and Holt 1996), should be an important for the development of 
more accurate models and of strategies to fight resistance.  
One of the assumptions of the model described in Figure 6.1 is that the 
genes for resistance can be transferred and lost. These properties are consistent 
with integration and excision properties of the mobile genetic elements that 
usually carry resistance (Syvanen 1984; Recchia and Hall 1997; Mahillon and 
Chandler 1998; Deurenberg et al. 2007), however the rate of transfer and loss of 
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mobile genetic elements is still an under-explored topic (Frost et al. 2005; 
Sørensen et al. 2005). Estimating the extent to which this assumption is true 
requires specific measurements that are not available in current reports (Naimi et 
al. 2003; Rupp and Fey 2003; Lindsay and Holden 2006; Robicsek et al. 2006; 
Tenover 2006; Klevens et al. 2007; Control 2010; Colomer-Lluch et al. 2011). 
Clinical studies identify the fraction of infection that are caused by antibiotic-
resistant bacteria, but usually do not measure how the resistance is carried. 
However, most reports on the topic describe resistance to be associated with 
plasmids. For example, β-lactamases, the most common genes for resistance in 
E. coli, are usually carried by a plasmid (Rupp and Fey 2003; Tenover 2006; 
Klevens et al. 2007; Control 2010; Colomer-Lluch et al. 2011). The resistance for 
quinolones was initially thought to be only caused by serial mutations in the 
chromosome and to be restricted to vertical transfers. However, 36 years after its 
introduction, researchers have detected a resistance carrying plasmid that is 
associated with the rise of high-level quinolone resistance, including multi-drug 
resistance (Robicsek et al. 2006; Control 2010). The methicillin resistance 
(mecA) in MRSA strains of S. aureus is carried in gene cassettes that contain 
recombinases able to excise and insert them into chromosomal regions (Lindsay 
and Holden 2006; Deurenberg et al. 2007). Moreover, most of the resistance to a 
second class of antibiotics is carried by a plasmid (Lindsay and Holden 2006). 
Resistance-carrying plasmids occur for other classes of antibiotics and 
!!
134!
organisms and are often the cause for the rise of multi-resistant strains (Tenover 
2006; Control 2010).  
In terms of host-population models, the use of mathematical models 
provides quantitative and predictive power to design optimal policies that would 
reduce the incidence of resistant pathogen and thus untreatable infection. The 
accuracy of those predictions, however, depends on how realistic the 
assumptions made by the models are. The key mechanisms for resistance 
dynamics still have to be deciphered, with different models providing different, 
and sometimes divergent, conclusions (Bonhoeffer et al. 1997; Bergstrom et al. 
2004; D'Agata et al. 2008; Beardmore and Pena-Miller 2010; Beardmore and 
Peña-Miller 2010; Bonhoeffer et al. 2010; Chow et al. 2010; Kouyos et al. 2011). 
For example, some mathematical models support drug cycling to combat 
antibiotic resistance (Beardmore and Peña-Miller 2010; Chow et al. 2010) and 
other models support alternative strategies, such as drug mixing (a strategy 
where each antibiotic class is randomly assigned to patients) or drug combination 
(Bonhoeffer et al. 1997; Bergstrom et al. 2004; Bonhoeffer et al. 2010). Drug 
cycling is the intervention with most experimental reports, showing an overall 
positive result (Brown and Nathwani 2005; Masterton 2005; Bonten and 
Weinstein 2006; Kollef 2006; Martínez et al. 2006; Cadena et al. 2007; Martinez 
2007; Francetić et al. 2008; Hedrick et al. 2008). The only experimental 
comparison between drug mixing and cycling has reported in favor of cycling 
(Martínez et al. 2006). Some studies have reported that the optimal strategy 
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might depend on the precise knowledge of the parameters (Beardmore and 
Pena-Miller 2010; Bonhoeffer et al. 2010), which might not be easily measurable. 
My analysis is based on experimentally measurable parameters that can guide 
hypothesis-based experiments to look for best strategies to fight antibiotic-
resistance.  
My analysis shows that the cost of resistance, used in the form of the 
resistance-decaying rate, might be a key parameter to solve the divergence 
between theoretical and experimental results on host-population models. In the 
case of the modified Bonhoeffer model (see section 7.1, Fig. 7.2), the addition of 
resistance attenuation term drastically change the predicted outcome for optimal 
strategy, from drug mixing or drug combination to drug cycling. In the case of the 
Bergstrom et al. model (Bergstrom et al. 2004), the cost of resistance (c1 and c2 
in Fig. 1 of reference (Bergstrom et al. 2004) ) is explicitly taken into account. 
However their conclusions are based on the assumption that this cost is zero 
(Fig. 2 of reference (Bergstrom et al. 2004) ). A different result can be reached by 
setting a positive value to this parameter. This fact is supported by Fig. 2C of 
Beardmore and Peña-Miller study (Beardmore and Peña-Miller 2010). Also, a 
recent model, based on the Bergstrom et al. model, concludes that the cycling 
strategy is more effective than mixing to reduce incidence of dual resistance 
(Chow et al. 2010). 
The best strategy (drug cycling, drug mixing, drug combinations or others) 
to deal with resistant pathogens probably depends on case-specific 
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characteristics. For example, in host population models, for cases in which the 
fitness difference between the resistant and sensitive strain is negligible, the 
model shown in (Bonhoeffer et al. 1997; Bergstrom et al. 2004) might be 
appropriate and drug cycling would not be a good strategy. However, when the 
resistant and sensitive strain have substantially different fitness, the model 
described in (Chow et al. 2010), the Bergstrom et al. model (Bergstrom et al. 
2004) with higher cost of resistance, or the modified Bonhoeffer et al. model 
(Bonhoeffer et al. 1997) (Fig. 7.2) could better indicate the optimal strategy.  
In the battle against antibiotic resistance, the use of mathematical models 
is important to transform the cumulative understanding of the mechanisms for 
acquisition and loss of resistance (Yeh et al. 2009; zur Wiesch et al. 2011; Chait 
et al. 2012) into potential strategies to treat infection caused by resistant 
pathogens. A recent review states the importance of plasmid-borne resistance 
and reports the lack of a theory that would suggest optimal strategies to control 
infection in this case (zur Wiesch et al. 2011). The analysis proposed in this 
paper contributes to this endeavor and suggests experimentally measurable 
parameters, making it easier to test hypotheses empirically. This analysis 
suggests that further iterations of empirical and mathematical studies will help 
understand how specific resistance mechanisms should be incorporated into 
models to enable improved policies for fighting resistance. 
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